Crizotinib (PF-02341066)

Name: Crizotinib (PF-02341066)
Brand: Selleck Chemicals
SKU: S1068
Rating: 5 (306 reviews)

For research use only.

Licensed by Pfizer Catalog No.S1068

306 publications

Crizotinib (PF-02341066) Chemical Structure

CAS No. 877399-52-5

Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively. It is also a potent ROS1 inhibitor with Ki value less than 0.025 nM. Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines.

Selleck's Crizotinib (PF-02341066) has been cited by 306 publications

Cancer Cell, 2020, 13;37(1):104-122e12

PubMed: 31935369 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Cell, 2018, 174(4):856-869

PubMed: 30096312 ( click the link to review the publication )

Cancer Cell, 2018, 34(6):922-938

PubMed: 30537514 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(6):681-690

PubMed: 28437395 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

J Clin Oncol, 2016, 34(8):794-802

PubMed: 26215952 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Discov, 2015, 5(9):960-971

PubMed: 26036643 ( click the link to review the publication )

Cancer Discov, 2015, 10.1158/2159-8290.CD-15-0913

PubMed: 26566875 ( click the link to review the publication )

Cancer Cell, 2015, 27(3):397-408

PubMed: 25759024 ( click the link to review the publication )

Cancer Cell, 2015, 27(4):533-46

PubMed: 25873175 ( click the link to review the publication )

Cancer Discov, 2014, 4(12):1398-405

PubMed: 25266736 ( click the link to review the publication )

Cancer Cell, 2014, 26(2):207-21

PubMed: 25065853 ( click the link to review the publication )

Nat Med, 2013, 19(11):1469-1472

PubMed: 24162815 ( click the link to review the publication )

Nature, 2012, 26;487(7408):505-9.

PubMed: 22763448 ( click the link to review the publication )

Cell, 2012, 21;151(5):937-50.

PubMed: 23178117 ( click the link to review the publication )

Nat Med, 2012, 18(6):883-91

PubMed: 22635005 ( click the link to review the publication )

Nat Med, 2011, 17(9):1116-20

PubMed: 21822287 ( click the link to review the publication )

Cancer Cell, 2011, 19(5):679-90

PubMed: 21575866 ( click the link to review the publication )

Cancers (Basel), 2021, 13(3)E372

PubMed: 33498427 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )
Nat Commun, 2020, 11(1):5704

PubMed: 33177525 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5017

PubMed: 33024122 ( click the link to review the publication )

Nat Commun, 2020, 25;11(1):1556

PubMed: 32214092 ( click the link to review the publication )

Sci Adv, 2020, 22;6(21):eaaz8521

PubMed: 32494745 ( click the link to review the publication )

EMBO Mol Med, 2020, e11099

PubMed: 32558295 ( click the link to review the publication )

Clin Cancer Res, 2020, clincanres.2853.2020

PubMed: 33310890 ( click the link to review the publication )

Dev Cell, 2020, 4;53(3):344-357 e5

PubMed: 32302545 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-3608

PubMed: 32034073 ( click the link to review the publication )

Clin Cancer Res, 2020, 8

PubMed: 32269053 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cancer Res, 2020, canres.1992.2020

PubMed: 33203698 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2697

PubMed: 32967224 ( click the link to review the publication )

Cell Death Dis, 2020, 11(10):882

PubMed: 33082316 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

Cancer Discov, 2020, 1 pii: CD-19-1030

PubMed: 32238360 ( click the link to review the publication )

Front Immunol, 2020, 11:527750

PubMed: 33324391 ( click the link to review the publication )

Transl Lung Cancer Res, 2020, 9(5):1810-1821

PubMed: 33209603 ( click the link to review the publication )

Transl Lung Cancer Res, 2020, 9(5):1904-1914

PubMed: 33209611 ( click the link to review the publication )

Cancer Sci, 2020, 111(10):3813-3823

PubMed: 32735723 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(2):403-423

PubMed: 32195017 ( click the link to review the publication )

Oral Oncol, 2020, 112:105074

PubMed: 33142224 ( click the link to review the publication )
Lung Cancer, 2020, 144:20-29

PubMed: 32353632 ( click the link to review the publication )

J Cell Physiol, 2020, 10.1002/jcp.29463

PubMed: 31960422 ( click the link to review the publication )

J Cell Sci, 2020, 11;133(9) pii: jcs241505

PubMed: 32184261 ( click the link to review the publication )

Antiviral Res, 2020, 178:104790

PubMed: 32272175 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 10(1):218

PubMed: 31937834 ( click the link to review the publication )

Int J Biol Sci, 2020, 16(14):2595-2611

PubMed: 32792859 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.015891

PubMed: 33087447 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00513-3

PubMed: 32918045 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Cancer Cell Int, 2020,

PubMed: 32874131 ( click the link to review the publication )

Oncol Rep, 2020, 43(3):817-826

PubMed: 32020234 ( click the link to review the publication )

Biomed Res Int, 2020, 2020:2046248

PubMed: 33376716 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Anticancer Res, 2020, 40(1):109-119

PubMed: 31892559 ( click the link to review the publication )

Anticancer Res, 2020, 40(3):1395-1403

PubMed: 32132036 ( click the link to review the publication )

Blood Adv, 2020, 4(5):819-829

PubMed: 32126142 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):549-559

PubMed: 31941753 ( click the link to review the publication )

NPJ Precis Oncol, 2020, 4:21

PubMed: 32802958 ( click the link to review the publication )

Hemasphere, 2020, 4(6):e497

PubMed: 33196013 ( click the link to review the publication )

Neoplasia, 2020, 22(10):470-483

PubMed: 32818841 ( click the link to review the publication )

J Thorac Oncol, 2020, 15(5):752-765

PubMed: 31972351 ( click the link to review the publication )

Oncogenesis, 2020, 9(7):64

PubMed: 32632141 ( click the link to review the publication )
Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3991

PubMed: 31488816 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4343

PubMed: 31554817 ( click the link to review the publication )

Clin Cancer Res, 2019, clincanres.1486.2019

PubMed: 31636099 ( click the link to review the publication )

EMBO Mol Med, 2019, 10.15252/emmm.201910581

PubMed: 31633304 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1667

PubMed: 31548343 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31776128 ( click the link to review the publication )

Cancer Res, 2019, 79(3):546-556

PubMed: 30538120 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1104

PubMed: 31585938 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Oncogene, 2019, 101038/s41388-019-1136-4

PubMed: 31804622 ( click the link to review the publication )

Oncogene, 2019, 38(11):1936-1950

PubMed: 30390071 ( click the link to review the publication )

EBioMedicine, 2019, 42:326-339

PubMed: 30879923 ( click the link to review the publication )

Cancers (Basel), 2019,

PubMed: 31072019 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)E104

PubMed: 30658414 ( click the link to review the publication )

Cell Death Dis, 2019, 10(9):663

PubMed: 31506424 ( click the link to review the publication )

Cell Death Dis, 2019, 10(2):139

PubMed: 30760701 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(3):718-725

PubMed: 30755456 ( click the link to review the publication )

Front Oncol, 2019, 9:579

PubMed: 31334113 ( click the link to review the publication )

Front Oncol, 2019, 9:579

PubMed: 31380285 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )
Biochem Pharmacol, 2019, 166:128-138

PubMed: 31078602 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz123

PubMed: 31132080 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(17)

PubMed: 31480591 ( click the link to review the publication )

Sci Rep, 2019, 9(1):19353

PubMed: 31852910 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882684 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 383:114768

PubMed: 31639374 ( click the link to review the publication )

Invest New Drugs, 2019, 10.1007/s10637-019-00795-3

PubMed: 31124056 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):1044

PubMed: 31690270 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):1231-1240

PubMed: 30653748 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):951-962

PubMed: 30309221 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Transl Oncol, 2019, 12(1):116-121

PubMed: 30290287 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 511(2):260-265

PubMed: 30791979 ( click the link to review the publication )

Future Oncol, 2019, 15(22):2585-2593

PubMed: 31339066 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 31540894 ( click the link to review the publication )

Oncotarget, 2019, 10(65):6981-6996

PubMed: 31857852 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(10):1753-1765

PubMed: 31279006 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

J Clin Invest, 2018, 128(9):4086-4097

PubMed: 29990309 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3126-3136

PubMed: 29618618 ( click the link to review the publication )

Leukemia, 2018, 32(9):1994-2007

PubMed: 29588546 ( click the link to review the publication )
Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Cell Syst, 2018, 6(3):329-342

PubMed: 29550255 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(12):2732-2739

PubMed: 29559559 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Cell Death Differ, 2018, 25(12):2053-2070

PubMed: 29515255 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459283 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):974

PubMed: 30250188 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):262

PubMed: 29449529 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(11-:2271-2284

PubMed: 30135214 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2622-2632

PubMed: 30282811 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):931-942

PubMed: 29440449 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):222-231

PubMed: 29054983 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(4):471-480

PubMed: 29440231 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(1):183-191

PubMed: 29416931 ( click the link to review the publication )

Mol Pharm, 2018, 15(5):1892-1900

PubMed: 29595984 ( click the link to review the publication )

Front Oncol, 2018, 8:460

PubMed: 30464927 ( click the link to review the publication )

Sci Rep, 2018,

PubMed: 29849102 ( click the link to review the publication )

Cancer Gene Ther, 2018, 26(1-2):1-10

PubMed: 29925897 ( click the link to review the publication )

Cancer Discov, 2018, 8(6):714-729

PubMed: 29650534 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(8):1541-1550

PubMed: 30210922 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Cancer Commun (Lond), 2018, 38(1):19

PubMed: 29764505 ( click the link to review the publication )

Cancer Res Treat, 2018, 50(2):599-613

PubMed: 28675026 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 82(2):251-263

PubMed: 29855693 ( click the link to review the publication )
Pediatr Blood Cancer, 2018, 65(8):e27094

PubMed: 29697184 ( click the link to review the publication )

Oncol Lett, 2018, 16(5):5983-5991

PubMed: 30333869 ( click the link to review the publication )

Oncol Lett, 2018, 16(5):5992-5996

PubMed: 30333870 ( click the link to review the publication )

Oncotarget, 2018, 9(43-:27242-27255

PubMed: 29930762 ( click the link to review the publication )

Oncolytic Virother, 2018, 7:107-116

PubMed: 30538967 ( click the link to review the publication )

J Thorac Oncol, 2017, S1556-0864(17)30365-9

PubMed: 28502721 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3551-3563

PubMed: 28428274 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3502-3512

PubMed: 28512244 ( click the link to review the publication )

Cell Rep, 2017, 21(11):3298-3309

PubMed: 29241554 ( click the link to review the publication )

Oncogene, 2017,

PubMed: 28759046 ( click the link to review the publication )

Oncogene, 2017, 36(38):5407-5420

PubMed: 28534512 ( click the link to review the publication )

J Pathol, 2017, 243(3):307-319

PubMed: 28741662 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e3013

PubMed: 28837150 ( click the link to review the publication )

Br J Cancer, 2017, 117(12):1787-1797

PubMed: 29024938 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2234-2245

PubMed: 28729401 ( click the link to review the publication )

Oncologist, 2017, 22(2):158-164

PubMed: 28167572 ( click the link to review the publication )

Sci Rep, 2017, 7:44206

PubMed: 28287179 ( click the link to review the publication )

Am J Cancer Res, 2017, 7(2):203-217

PubMed: 28337371 ( click the link to review the publication )

BMC Cancer, 2017, 17(1):191

PubMed: 28292264 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

Molecules, 2017, 22(12)

PubMed: 29206199 ( click the link to review the publication )

Medchemcomm, 2017, 8(10):1914-1918

PubMed: 30108712 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )
Oncol Lett, 2017, 13(6):4085-4092

PubMed: 28599410 ( click the link to review the publication )

Cardiooncology, 2017, 3

PubMed: 28217366 ( click the link to review the publication )

Oncotarget, 2017, 8(70):114945-114955

PubMed: 29383132 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51675-51687

PubMed: 28881678 ( click the link to review the publication )

Blood, 2016, 128(9):1234-45

PubMed: 27297792 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Nat Commun, 2016, 7:10690

PubMed: 26891683 ( click the link to review the publication )

J Clin Invest, 2016, 3;126(10):3739-3757

PubMed: 27571409 ( click the link to review the publication )

Nat Commun, 2016, 7:11815

PubMed: 27283993 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1273-1281

PubMed: 27068398 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(7):1787-99

PubMed: 26667487 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(22):5527-5538

PubMed: 27780853 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(24):6031-6038

PubMed: 27091406 ( click the link to review the publication )

Cancer Res, 2016,

PubMed: 27197184 ( click the link to review the publication )

Cancer Res, 2016, 76(6):1506-16

PubMed: 26719536 ( click the link to review the publication )

Cancer Res, 2016, 76(4):974-83

PubMed: 26837769 ( click the link to review the publication )

J Pathol, 2016, 238(4):543-9

PubMed: 26606880 ( click the link to review the publication )

Cancer Discov, 2016, 6(12):1334-1341

PubMed: 27694386 ( click the link to review the publication )

Oncoimmunology, 2016, 5(3):e1094598

PubMed: 27141355 ( click the link to review the publication )

Oncoimmunology, 2016,

PubMed: 27141364 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2453-2463

PubMed: 27748897 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2236-2244

PubMed: 27748834 ( click the link to review the publication )
Cellular Signalling, 2016, 19;28(6):652-662

PubMed: 27006333 ( click the link to review the publication )

Endocrine, 2016, 53(1):145-56

PubMed: 26370117 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2016, 77(3):623-8

PubMed: 26849637 ( click the link to review the publication )

PLoS One, 2016, 11(11):e0165983

PubMed: 27832137 ( click the link to review the publication )

Vet Parasitol, 2016, 227:64-8

PubMed: 27523939 ( click the link to review the publication )

Int J Surg, 2016, 28:179-84

PubMed: 26957017 ( click the link to review the publication )

World J Clin Oncol, 2016, 7(6):425-432

PubMed: 28008383 ( click the link to review the publication )

Sci Rep, 2016, 10.1038/srep24817

PubMed: 27102549 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84675-84687

PubMed: 27835869 ( click the link to review the publication )

Springerplus, 2016, 5:348

PubMed: 27057482 ( click the link to review the publication )

Sci Rep, 2016, 6:32992

PubMed: 27623107 ( click the link to review the publication )

Tumour Biol, 2016, 37(4):4373-82

PubMed: 26499783 ( click the link to review the publication )

Oncotarget, 2016, 7(46):75968-75980

PubMed: 27732954 ( click the link to review the publication )

Oncotarget, 2016, 7(20):29199-210

PubMed: 27078848 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Oncotarget, 2016, 7(17):23715-29

PubMed: 27009859 ( click the link to review the publication )

Blood, 2015, 126(26):2821-31

PubMed: 26531163 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )

Nat Commun, 2015, 6:7002

PubMed: 25926053 ( click the link to review the publication )

Cancer Res, 2015, 10.1158/0008-5472.CAN-15-0370

PubMed: 25952648 ( click the link to review the publication )

Cancer Res, 2015, 75(14):2916-27

PubMed: 26018086 ( click the link to review the publication )

Elife, 2015,

PubMed: 25686219 ( click the link to review the publication )

PLoS Genet, 2015, 11(9):e1005533

PubMed: 26393505 ( click the link to review the publication )

Cancer Discov, 2015,

PubMed: 26432108 ( click the link to review the publication )
Oncoimmunology, 2015, 5(3):e1108514

PubMed: 27141364 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(11-:2433-40

PubMed: 26351321 ( click the link to review the publication )

Radiother Oncol, 2015, 114(2):173-81

PubMed: ( click the link to review the publication )

Radiother Oncol, 2015,

PubMed: 25592111 ( click the link to review the publication )

Radiother Oncol, 2015, 114(2):173-81

PubMed: ( click the link to review the publication )

Cancer Sci, 2015, 106(3):244-52

PubMed: 25581823 ( click the link to review the publication )

Lung Cancer, 2015, 90(3):590-7

PubMed: 26547802 ( click the link to review the publication )

J Cell Physiol, 2015, 230(9):2281-98

PubMed: 25704960 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 285(1):51-60

PubMed: 25841593 ( click the link to review the publication )

Int J Oncol, 2015, 46(3):1025-30

PubMed: 25502629 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0132330

PubMed: 26147305 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0124283

PubMed: 25919140 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0121378

PubMed: 25874976 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:375-83

PubMed: 25678804 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 10.1016/j.bbrc.2015.02.114

PubMed: 25735977 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25909220 ( click the link to review the publication )

Oncotarget, 2015, 6(27):24320-32

PubMed: 26172300 ( click the link to review the publication )

Cell, 2015, 162(6):1271-85

PubMed: 26359985 ( click the link to review the publication )

Oncotarget, 2015, 6(37):40268-82

PubMed: 26384345 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2015, 18(6):330-9

PubMed: 26104888 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26375439 ( click the link to review the publication )

Oncotarget, 2015, 6(37):40268-82

PubMed: 26384345 ( click the link to review the publication )

Oncotarget, 2015, 6(30):28774-89

PubMed: 26299615 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(11):1638-46

PubMed: 25144242 ( click the link to review the publication )
J Thorac Oncol, 2014, 9(11):1638-46

PubMed: ( click the link to review the publication )

J Thorac Oncol, 2014, 9(6):775-83

PubMed: 24828661 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(11):2898-909

PubMed: 24714777 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(18):4806-15

PubMed: 25052479 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(44):E4706-15

PubMed: 25331893 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(11):2898-909

PubMed: 24714777 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Elife, 2014, 10.7554/eLife.03751

PubMed: 25551293 ( click the link to review the publication )

Cancer Lett, 2014, 351(2):215-21

PubMed: 24887559 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(1):134-43

PubMed: 24170771 ( click the link to review the publication )

Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-14-0274

PubMed: 25349307 ( click the link to review the publication )

Mol Oncol, 2014, 9(1):260-9

PubMed: 25226813 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Cancer Sci, 2014, 105(5):528-36

PubMed: 24612061 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: 25426675 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2014, 140(4):589-98

PubMed: 24509625 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2014, 74(5):1023-8

PubMed: 25205428 ( click the link to review the publication )

PLoS One, 2014, 9(11):e112148

PubMed: 25386922 ( click the link to review the publication )

PLoS One, 2014, 9(10):e111146

PubMed: 25343454 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

Biomed Res Int, 2014, 2014:764981

PubMed: 25057499 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.10.126

PubMed: ( click the link to review the publication )

Jpn J Clin Oncol, 2014, 44(10):963-8

PubMed: 25170107 ( click the link to review the publication )

Future Oncol, 2014, 10(2):211-7

PubMed: 24490607 ( click the link to review the publication )
Leuk Res, 2014, 38(4):503-8

PubMed: 24486291 ( click the link to review the publication )

Korean J Parasitol, 2014, 52(4):439-41

PubMed: 25246725 ( click the link to review the publication )

Oncotarget, 2014, 5(13):4920-8

PubMed: 24952482 ( click the link to review the publication )

Urol Oncol, 2014, 32(6):877-84

PubMed: 24929890 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Int J Cancer, 2013, 133(2):427-36

PubMed: 23335077 ( click the link to review the publication )

Int J Cancer, 2013, 132(2):E74-84

PubMed: 22948846 ( click the link to review the publication )

Br J Cancer, 2013, 109(12):3084-91

PubMed: 24149177 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

PLoS Genet, 2013, 9(11):e1003958

PubMed: 24278035 ( click the link to review the publication )

Mol Oncol, 2013, 7(6):1093-102

PubMed: 23993685 ( click the link to review the publication )

ACS Chem Biol, 2013, 9(3):777-84

PubMed: 24397822 ( click the link to review the publication )

J Am Heart Assoc, 2013, 2(6):e000376

PubMed: 24308935 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1640-6

PubMed: 24118504 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1618-25

PubMed: 24112719 ( click the link to review the publication )

Sci Rep, 2013, 3:3450

PubMed: 24356251 ( click the link to review the publication )

Int J Cardiol, 2013, 168(4):3486-94

PubMed: 23680593 ( click the link to review the publication )

Mol Pharmacol, 2013, 83(4):882-93

PubMed: 23371912 ( click the link to review the publication )

Clin Chem Lab Med, 2013, 51(9):1843-8

PubMed: 23612660 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2013, 272(1):245-55

PubMed: 23707608 ( click the link to review the publication )

J Cell Biochem, 2013, 114(4):816-22

PubMed: 23060267 ( click the link to review the publication )

Molecules, 2013, 18(12):15412-21

PubMed: 24335618 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82236

PubMed: 24349229 ( click the link to review the publication )
PLoS One, 2013, 8(12):e84700

PubMed: 24386407 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56010

PubMed: 23418494 ( click the link to review the publication )

Oncotarget, 2013, 4(12):2237-48

PubMed: 24163262 ( click the link to review the publication )

Tumour Biol, 2013, 35(4):3229-35

PubMed: 24293393 ( click the link to review the publication )

Springerplus, 2013, 2:497

PubMed: 24102046 ( click the link to review the publication )

CELON PHARMA, 2013, 2013

PubMed: ( click the link to review the publication )

Sci Transl Med, 2012, 4(120):120ra17

PubMed: 22277784 ( click the link to review the publication )

Br J Pharmacol, 2012, 166(5):1669-83

PubMed: 22233293 ( click the link to review the publication )

Neoplasia, 2012, 14(7):572-84

PubMed: 22904675 ( click the link to review the publication )

ACS Chem Biol, 2012, 7(8):1429-35

PubMed: 22625864 ( click the link to review the publication )

J Biol Chem, 2012, 287(18):14586-97

PubMed: 22418436 ( click the link to review the publication )

J Biol Chem, 2012, 287(47):39812-23

PubMed: 23024367 ( click the link to review the publication )

PLoS One, 2012, 7(2):e30820

PubMed: 22319590 ( click the link to review the publication )

Pediatr Blood Cancer, 2012, 17(23):7394-401

PubMed: 22488797 ( click the link to review the publication )

Clin Cancer Res, 2011, 59(3):440-7

PubMed: 21948233 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5255-64

PubMed: 21697284 ( click the link to review the publication )

J Biomol Screen, 2011, 16(2):141-54

PubMed: 21297102 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Purity & Quality Control

Choose Selective c-Met Inhibitors

Biological Activity

Description

Targets

ROS1 ^[6] (Cell-free assay)	c-Met ^[1] (A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)	ALK ^[1] (Karpas299 cells)
<0.025 nM(Ki)	11 nM	24 nM

In vitro

PF-2341066 displays similar potency against c-Met phosphorylation in mIMCD3 mouse or MDCK canine epithelial cells with IC50 of 5 nM and 20 nM, respectivly. PF-2341066 shows improved or similar activity against NIH3T3 cells engineered to express c-Met ATP-binding site mutants V1092I or H1094R or the P-loop mutant M1250T with IC50 of 19 nM, 2 nM and 15 nM, respectively, compared with NIH3T3 cells expressing wild-type receptor with IC50 of 13 nM. In contrast, a marked shift in potency of PF-2341066 is observed against cells engineered to express c-Met activation loop mutants Y1230C and Y1235D with IC50 of 127 nM and 92 nM, respectively, compared with wild-type receptor. PF-2341066 also potently prevents the phosphorylation of c-Met in NCI-H69 and HOP92 cells, with IC50 of 13 nM and 16 nM, respectively, which express the endogenous c-Met variants R988C and T1010I, respectively. PF-2341066 is >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ∼40- to 60-fold selective for Tie2, TrkA, and TrkB, all compared with c-Met. PF-2341066 is 20- to 30-fold selective for RON and Axl RTKs. In contrast, PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion variant of the ALK RTK expressed by the KARPAS299 human anaplastic large cell lymphoma (ALCL) cell line. PF-2341066 inhibits c-Met–dependent neoplastic phenotypes of cancer cells and angiogenic phenotypes of endothelial cells. PF-2341066 suppresses human GTL-16 gastric carcinoma cell growth with IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with IC50 of 8.4 nM. PF-2341066 inhibits HGF-stimulated human NCI-H441 lung carcinoma cell migration and invasion with IC50 of 11 nM and 6.1 nM, respectively. PF-2341066 inhibits MDCK cell scattering with IC50 of 16 nM. PF-2341066 prevents HGF-stimulated c-Met phosphorylation, cell survival, and Matrigel invasion with IC50 of 11 nM, 14 nM and 35 nM, respectively. In addition, PF-2341066 prevents serum-stimulated HMVEC branching tubulogenesis (formation of vascular tubes) in fibrin gels. ^[1] PF-2341066 also potently inhibits NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells with an IC50 of 24 nM. PF-2341066 potently prevents cell proliferation, which is associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells with IC50 of 30 nM, but not ALK-negative lymphoma cells. ^[2] Besides, PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (i.e., proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
SU-DHL1	NU\4b5dLS3m2b4TvfIlkKEG\|c3H5				NUPaO4VXS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW1VvRFjMNUBk\WyuczDlfJBz\XO\|aX7nJGFNUyClb3X4dJJme3OrbnegUnBOKHerdHigTWM2OCCxZjCwMlAyKM7:TR?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTV5MkW4PUc,OjF3N{K1PFk9N2F-
BAF3	NVvvVIlDS3m2b4TvfIlkKEG\|c3H5		MmL2OFghcA>?	MVrEUXNQ	NILBdGtEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSUZ\|IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRiY3;lfJBz\XO\|aX7nJGVOVDRid3n0bEBKSzVyIH;mJFAvPjJizszN	NEHSXGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUW3NlU5QSd-MkG1O\|I2QDl:L3G+
BAF3	NV3BWmU4S3m2b4TvfIlkKEG\|c3H5		MVy0PEBp	M1vzPWROW09?	MkW0R5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEGOSzDMNVE6Pk1ibYX0ZY51KGOxZYjwdoV{e2mwZzDFUWw1KHerdHigTWM2OCCxZjCyMlIh\|ryP	NFzPWVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUW3NlU5QSd-MkG1O\|I2QDl:L3G+
BAF3	NYm5V5NrS3m2b4TvfIlkKEG\|c3H5		NYnIZ5VFPDhiaB?=	Mn\kSG1UVw>?	MXrDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochTU2OND3BUGshf2m2aDDJR\|UxKG:oIECuNlgh\|ryP	NGD2Nok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUW3NlU5QSd-MkG1O\|I2QDl:L3G+
Kelly	M{XKOmN6fG:2b4jpZ{BCe3OjeR?=			NWX6S2p1TE2VTx?=	M4PmNGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtmdGy7IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRid3n0bEBKSzVyIH;mJFAvPDJizszN	NGPKfmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUW3NlU5QSd-MkG1O\|I2QDl:L3G+
SH-SY5Y	MlzGR5l1d3SxeHnjJGF{e2G7			M4\NfmROW09?	NG[2b4FEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUC2VWUXZJINmdGy\|IHX4dJJme3OrbnegRWxMKEZzMUe0UEBufXSjboSge4l1cCCLQ{WwJI9nKDBwNUOg{txO	MnnsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3N{K1PFkoRjJzNUeyOVg6RC:jPh?=
SMS-KCN	M3;G[GN6fG:2b4jpZ{BCe3OjeR?=			NWPFdph6TE2VTx?=	MUXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTUXMuU0OQIHPlcIx{KGW6cILld5NqdmdiQVzLJHIyOjd3UTDteZRidnRid3n0bEBKSzVyIH;mJFAvQTFizszN	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTV5MkW4PUc,OjF3N{K1PFk9N2F-
BAF3	MVHDfZRwfG:6aXOgRZN{[Xl?		NFiwNWk1QCCq	M1XrW2ROW09?	MXPDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochXGWuLVHMT{B4cXSqIFnDOVAhd2ZiMD6xPUDPxE1?	NGf5bXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUW3NlU5QSd-MkG1O\|I2QDl:L3G+
3T3	MYXGeY5kfGmxbjDBd5NigQ>?		MXKxJIg>	M2r2fGROW09?	MYTJcohq[mm2aX;uJI9nKFKRTjDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yODFOwG0>	MnLoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MUK0NVQoRjJzOEGyOFE1RC:jPh?=
3T3-E	NXrNT5k2TnWwY4Tpc44hSXO\|YYm=		MmjCNUBp	MUDEUXNQ	NESy[GpKdmirYnn0bY9vKG:oIGTJSVIh[XO\|ZYPz[YQh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwNES4JO69VQ>?	M{fh[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEGyOFE1Lz5{MUixNlQyPDxxYU6=
A549	MoL3T4lv[XOnIFHzd4F6		NF3POnAyKGh?	MYLEUXNQ	NXjUW4RoUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDjMW1GXCCtaX7hd4Uh\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhUEeILXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMEig{txO	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThzMkSxOEc,OjF6MUK0NVQ9N2F-
BAF3-BCL	NI\Ze4NHfW6ldHnvckBCe3OjeR?=		NHzC[oQyKGh?	NYnVZ3c5TE2VTx?=	MY\Jcohq[mm2aX;uJI9nKEGETDDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOS5zNUmg{txO	MnPFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MUK0NVQoRjJzOEGyOFE1RC:jPh?=
HEK293	MmLQSpVv[3Srb36gRZN{[Xl?		NUHGNpBtOSCq	NIH3dFVFVVOR	NXXJfYpwUW6qaXLpeIlwdiCxZjDBXGwh[XO\|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIECuNlk1KM7:TR?=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThzMkSxOEc,OjF6MUK0NVQ9N2F-
HEK293	NVHtd\|l3TnWwY4Tpc44hSXO\|YYm=		NFzyZlUyKGh?	MXzEUXNQ	NGLZe\|NKdmirYnn0bY9vKG:oIFnSJIF{e2W\|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iB{Lki4O{DPxE1?	NHHr[mc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUixNlQyPCd-MkG4NVI1OTR:L3G+
Jurkat	MX\GeY5kfGmxbjDBd5NigQ>?		MnTQNUBp	NXHNUFU2TE2VTx?=	NEXYNGlKdmirYnn0bY9vKG:oIFzDT{Bie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMj63OFEh\|ryP	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThzMkSxOEc,OjF6MUK0NVQ9N2F-
KARPAS299	NXvXcFZ6U2mwYYPlJGF{e2G7		NHnUb\|EyKGh?	NYTkWXZ5TE2VTx?=	M4K4S2lvcGmkaYTpc44hd2ZiQVzLJIF{e2W\|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCyJO69VQ>?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThzMkSxOEc,OjF6MUK0NVQ9N2F-
PAE	MlTYSpVv[3Srb36gRZN{[Xl?		M{Xsd\|EhcA>?	MWPEUXNQ	MUTJcohq[mm2aX;uJI9nKFSUS1KgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwM{m5JO69VQ>?	NIXuZ5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUixNlQyPCd-MkG4NVI1OTR:L3G+
PAE	MlH5SpVv[3Srb36gRZN{[Xl?		Mo\KNUBp	MW\EUXNQ	M4PkcGlvcGmkaYTpc44hd2ZiVGLLRUBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD61PEDPxE1?	M3XwTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEGyOFE1Lz5{MUixNlQyPDxxYU6=
BAF3	Mn63SpVv[3Srb36gRZN{[Xl?		NWS0Uot5Oi1\|IHS=	MmH3SG1UVw>?	NHv5dIVKdmirYnn0bY9vKG:oIGTFUE1nfXOnZDDpcpN2dGmwIILlZ4VxfG:{IHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOS54NEOg{txO	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd2MkK1Nkc,OjN5NEKyOVI9N2F-
BAF3	M4PIfmZ2dmO2aX;uJGF{e2G7		NYfSVVM{Oi1\|IHS=	M2r1WmROW09?	NYK5TpA{UW6qaXLpeIlwdiCxZjDOVG0u\nW\|ZXSgRWxMKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKDRkOgZ4VtdHNiYX\0[ZIhOiC2bzCzJIRigXNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6KHerdHigTWM2OCCxZjCwMlE2ODhizszN	NGDidFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e0NlI2Oid-MkO3OFIzPTJ:L3G+
BAF3	MkDMSpVv[3Srb36gRZN{[Xl?		NULvOJI4Oi1\|IHS=	MWLEUXNQ	MX\DfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIFnfGW{IEKgeI8hOyCmYYnzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTD3bZRpKEmFNUCgc4YhOy52N{mg{txO	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd2MkK1Nkc,OjN5NEKyOVI9N2F-
KARPAS299	NXfGSZluS3m2b4TvfIlkKEG\|c3H5		NVHYdIFGOi1\|IHS=	Ml7MSG1UVw>?	Mn3QTWM2OD1yLkC2OFIh\|ryP	NYfzZWszRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3OFIzPTJpPkKzO\|QzOjV{PD;hQi=>
EBC1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mlv0O\|IhcA>?	MoLGSG1UVw>?	M{jQbGlEPTB;MD6wNlMh\|ryP	NYraO2RMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5PVM{OjhpPkKzPVk{OzJ6PD;hQi=>
HCT116	MkjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M13zblczKGh?	MXTEUXNQ	NHm1b4FKSzVyPUG0MlgzKM7:TR?=	NITFT5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m5N\|MzQCd-MkO5PVM{Ojh:L3G+
MCF7	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWS3NkBp	MX;EUXNQ	M4jLfGlEPTB;OT61PEDPxE1?	NYXGV5c3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5PVM{OjhpPkKzPVk{OzJ6PD;hQi=>
MDA-MB-231	M{fqNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2XSTVczKGh?	MmT1SG1UVw>?	NXOyfHN6UUN3ME2xNE45KM7:TR?=	NUHRZ5N6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5PVM{OjhpPkKzPVk{OzJ6PD;hQi=>
MKN45	NI\pN21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWL3WnpnPzJiaB?=	NV\TN3dzTE2VTx?=	NFfIbVlKSzVyPUCuNFE{KM7:TR?=	M3\zTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUmzN\|I5Lz5{M{m5N\|MzQDxxYU6=
NCI-H441	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGHNb484OiCq	NYXwfZhuTE2VTx?=	NX3yNXA2UUN3ME2xO{4zPSEQvF2=	Mli3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7OUOzNlgoRjJ\|OUmzN\|I5RC:jPh?=
NCI-H661	M3rkVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkjCO\|IhcA>?	NFfibG5FVVOR	MYrJR\|UxRTFzLkS3JO69VQ>?	Mnq1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7OUOzNlgoRjJ\|OUmzN\|I5RC:jPh?=
SK-MEL-28	M2TmSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIq1UHM4OiCq	M3;TUWROW09?	NGjpNVFKSzVyPUGwMlk4KM7:TR?=	MlW2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7OUOzNlgoRjJ\|OUmzN\|I5RC:jPh?=
SKOV3	M2jScmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYW3NkBp	MkWxSG1UVw>?	MU\JR\|UxRTF{Lki1JO69VQ>?	MnXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7OUOzNlgoRjJ\|OUmzN\|I5RC:jPh?=
SNU5	MmnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkK0O\|IhcA>?	MXPEUXNQ	MVHJR\|UxRTBwMEG2JO69VQ>?	M4m5UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUmzN\|I5Lz5{M{m5N\|MzQDxxYU6=
Antiproliferative assay	M4nvRWVDSzF?		NU\ofGdiPzJiaILz		MnLlRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCHQlOxJINmdGy\|IHX4dJJme3Orbneg[YxmfmG2ZXSgcIV3\Wy\|IH;mJINwdnO2aYT1eIl3\Wy7IHHjeIl3\SClLV3leEBi\nSncjC3NkBpenNiYomgV3JDKGG\|c3H5MEBKSzVyIE2gNE4xPTNizszNMi=>	NEmzcJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mki2N\|UzQSd-MkK4OlM2Ojl:L3G+
Function assay	NGWyTotMSVKSQWOyPVk>		MXe3NkBpenN?		M2fPXmlvcGmkaYTpc44hd2ZiQVzLMYZ2e2mxbjDkdol3\W5iY3XscEBxem:uaX\ldoF1cW:wIHnuJIh2dWGwIFvBVnBCWzJ7OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzKEeubzDhd5NigSxiSVO1NEA:KDBwME[yJO69VS5?	NWP2TFhMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0N\|I6ODlpPkK0OFMzQTB7PD;hQi=>
Function assay	MU\OTWguO1R\|		M{P5OVEhcHJ?		NGDkU4pKdmirYnn0bY9vKG:oIHj1cYFvKHerbHSgeJlx\SCHTVy0MYZ2e2WmIFHMT{BmgHC{ZYPz[YQhcW5ibX;1d4UhVkmKLUPUN{Bk\WyuczDhd5Nme3OnZDDhd{BxcG:\|cHjvdplt[XSnZDDBUGshdGW4ZXygZYZ1\XJiMTDodkBjgSC\|YX7ke4lkcCCHTFnTRUwhUUN3MDC9JFAvODhizszNMi=>	MmD5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2M{K5NFkoRjJ2NEOyPVA6RC:jPh?=
Function assay	NGO0dnFPS0lvSEOxNlI>		MVy3NkBpenN?		NFPqfohKdmirYnn0bY9vKG:oIFHMT{1nfXOrb36g[JJqfmWwIHPlcIwheHKxbHnm[ZJifGmxbjDpckBpfW2jbjDOR2kuUDNzMkKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmeiCJbH:gZZN{[XluIFnDOVAhRSByLkGwPEDPxE1w	M2TGPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEOyPVA6Lz5{NESzNlkxQTxxYU6=
Function assay	NFnCVXRPS0lvSEKyNlg>		MVG3NkBpenN?		NH\OZVFKdmirYnn0bY9vKG:oIFHMT{1nfXOrb36g[JJqfmWwIHPlcIwheHKxbHnm[ZJifGmxbjDpckBpfW2jbjDOR2kuUDJ{MkigZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmeiCJbH:gZZN{[XluIFnDOVAhRSByLkGxPEDPxE1w	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR\|MkmwPUc,OjR2M{K5NFk9N2F-
Function assay	MorwUmlJNTOWMx?=		NFzxSJQyKGi{		M4XEc2lvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugSlEyPzSOIH31eIFvfCCneIDy[ZN{\WRiaX6gcY92e2ViTlnIMVNVOyClZXzsd{Bie3Onc4Pl[EBieyCyaH;zdIhwNUGOSzDs[ZZmdCCjZoTldkAyKGi{IHL5JJNidmS5aXPoJGVNUVODLDDJR\|UxKD1iMD6xOlUh\|ryPLh?=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR\|MkmwPUc,OjR2M{K5NFk9N2F-
Function assay	NXvjTFlnVkmKLUPUNy=>		NWewemlNOSCqch?=		NYK3RYoxUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BEOTF3NmmgcZV1[W62IHX4dJJme3OnZDDpckBud3W\|ZTDOTWguO1R\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IIDoc5NxcG9vQVzLJIxmfmWuIHHmeIVzKDFiaIKgZpkhe2GwZIfpZ4ghTUyLU1GsJGlEPTBiPTCwMlQ4QCEQvF2u	M4jFRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEOyPVA6Lz5{NESzNlkxQTxxYU6=
Function assay	MVLOTWguO1R\|		MYKxJIhz		NHLtbGxKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGcyOjZ7QTDteZRidnRiZYjwdoV{e2WmIHnuJI1wfXOnIF7JTE0{XDNiY3XscJMh[XO\|ZYPz[YQh[XNicHjvd5Bpdy2DTFugcIV3\WxiYX\0[ZIhOSCqcjDifUB{[W6md3njbEBGVEmVQTygTWM2OCB;IECuOlA2KM7:TT6=	MknGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2M{K5NFkoRjJ2NEOyPVA6RC:jPh?=
Function assay	MVHOR2kuUDNzMkK=		MUS3NkBpenN?		MXTJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMhcGG{Yn;ybY5oKEGOSzDHNVI3QUFibYX0ZY51KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIhT2yxIHHzd4F6NCCLQ{WwJF0hOC54MkOg{txONg>?	NXnLNVR1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0N\|I6ODlpPkK0OFMzQTB7PD;hQi=>
Function assay	NGju[\|BPUUhvM2Sz		NVLCPHJ{OSCqch?=		Mo\3TY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDTNVIxPllibYX0ZY51KGW6cILld5Nm\CCrbjDtc5V{\SCQSVitN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKGGodHXyJFEhcHJiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSByLk[yOkDPxE1w	MoW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2M{K5NFkoRjJ2NEOyPVA6RC:jPh?=
Function assay	NYPqfGVVVkOLLVizNVIz		M4\UVFczKGi{cx?=		MUfJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMhcGG{Yn;ybY5oKEGOSzDMNVE6Pk1ibYX0ZY51KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIhT2yxIHHzd4F6NCCLQ{WwJF0hOC56M{ig{txONg>?	MlfKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2M{K5NFkoRjJ2NEOyPVA6RC:jPh?=
Function assay	NXfTco9YVkmKLUPUNy=>		NWr4dGxWOSCqch?=		MofGTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDMNVE6Pk1ibYX0ZY51KGW6cILld5Nm\CCrbjDtc5V{\SCQSVitN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKGGodHXyJFEhcHJiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSByLki0N{DPxE1w	NELBXWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESzNlkxQSd-MkS0N\|I6ODl:L3G+
Function assay	MnzEUmlJNTOWMx?=		NETERpoyKGi{		NGrYfWRKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGwyOTV{UjDteZRidnRiZYjwdoV{e2WmIHnuJI1wfXOnIF7JTE0{XDNiY3XscJMh[XO\|ZYPz[YQh[XNicHjvd5Bpdy2DTFugcIV3\WxiYX\0[ZIhOSCqcjDifUB{[W6md3njbEBGVEmVQTygTWM2OCB;IEGuNFI3KM7:TT6=	M1PI[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEOyPVA6Lz5{NESzNlkxQTxxYU6=
Function assay	M{D6VW5KUC1\|VEO=		NYDH[4ZKOSCqch?=		MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIEGxOVFVcW6\|IH31eIFvfCCneIDy[ZN{\WRiaX6gcY92e2ViTlnIMVNVOyClZXzsd{Bie3Onc4Pl[EBieyCyaH;zdIhwNUGOSzDs[ZZmdCCjZoTldkAyKGi{IHL5JJNidmS5aXPoJGVNUVODLDDJR\|UxKD1iMz6wN\|kh\|ryPLh?=	NGLIc\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESzNlkxQSd-MkS0N\|I6ODl:L3G+
Function assay	NYfqSFZtSkGIMx?=		NI[4Z2g4OiCqcoO=		MknnTY5pcWKrdHnvckBw\iCQUF2vRWxMKCi3bnvuc5dvKG:{aXfpckkhfHKjboPm[YN1\WRiaX6gcY92e2ViQlHGN{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCdM1jdMZRpgW2rZHnu[UBqdmOxcoDvdoF1cW:wIHHzd4F6NCCLQ{WwJF0hOC5yNUGg{txONg>?	NInPXGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES2PFY{Oid-MkS0Olg3OzJ:L3G+
Function assay	NHfLS3JDSUZ\|		MVO3NkBpenN?		NFzvW21KdmirYnn0bY9vKG:oIF7QUU9CVEtiKIXub45wf25ib4Lp[4lvMSC2cnHud4Zm[3SnZDDpckBud3W\|ZTDCRWY{KGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IGuzTH0ufGi7bXnkbY5mKGmwY3;ydI9z[XSrb36gZZN{[XluIFnDOVAhRSByLkC1NUDPxE1w	MmLmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2Nki2N\|IoRjJ2NE[4OlMzRC:jPh?=
Function assay	M{jQdGJCTjN?		M2Lie\|czKGi{cx?=		M4\i[WlvcGmkaYTpc44hd2ZiTmDNM2FNUyCOMUG5Om0hdXW2YX70JEh2dmuwb4fuJI9zcWerbjmgeJJidnOoZXP0[YQhcW5ibX;1d4UhSkGIMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBcO0ifLYTofY1q\GmwZTDpcoNwenCxcnH0bY9vKGG\|c3H5MEBKSzVyIE2gNE4zPiEQvF2u	NWS1NpNQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0Olg3OzJpPkK0OFY5PjN{PD;hQi=>
Cytotoxicity assay	MWXCRWY{		Mkf1O\|IhcHK\|		MVfDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBcO0ifLYTofY1q\GmwZTDpcoNwenCxcnH0bY9vKGG\|c3H5MEBKSzVyIE2gNE46QCEQvF2u	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR4OE[zNkc,OjR2Nki2N\|I9N2F-
Antiproliferative assay	NUnlZ3R2VkmKL{PUNy=>		NGHFdpI4OiCqcoO=		NVrNOVNDSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBkemm8b4TpcoljNXKnc3nzeIFvfCCvb4Xz[UBPUUhxM2SzJINmdGy\|IHjhdoJwemmwZzDFUWw1NUGOSzD2ZZJq[W62IEGgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFk2PCEQvF2u	M{W5clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{i1OFY2Lz5{NEe4OVQ3PTxxYU6=
Antiproliferative assay	NWD0ZVVTW1WSLV2y		M{nGcFczKGi{cx?=		MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOXUD3NNkBk\WyuczDoZZJjd3KrbnegUnBONUGOSzDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xO\|Qh\|ryPLh?=	MlrQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OEW0OlUoRjJ2N{i1OFY2RC:jPh?=
Antiproliferative assay	NGXVOJVPUUhxM2Sz		MoTEO\|IhcHK\|		NFX5NINCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JINzcXqxdHnubYIuemW\|aYP0ZY51KG2xdYPlJG5KUC9\|VEOgZ4VtdHNiaHHyZo9zcW6pIFXNUFQuSUyNII\hdolidnRiMT;MNVE6Pk1ibYX0ZY51KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjZyNjFOwG0v	NXi2SGNqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFU1PjVpPkK0O\|g2PDZ3PD;hQi=>
Function assay	NEDve3NPUUhvM2Sz		M4m1VVEhcHJ?		MV3Jcohq[mm2aX;uJI9nKHerbHSgeJlx\SCqdX3hckBGVUx2LX\1d4VlKEGOSzDlfJBz\XO\|ZXSgbY4hdW:3c3WgUmlJNTOWMzDj[YxteyCjc4Pld5Nm\CCjczDwbI9{eGixconsZZRm\CCDTFugcIV3\WxiYX\0[ZIhOSCqcjDifUB{[W6md3njbEBGVEmVQTygTWM2OCB;IECuNFgh\|ryPLh?=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDhzOUGxOkc,OjR6MUmxNVY9N2F-
Function assay	Ml3wUmlJNTOWMx?=		MXyxJIhz		MV7Jcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIF[xNVc1VCCvdYThcpQh\XiycnXzd4VlKGmwIH3veZNmKE6LSD2zWFMh[2WubIOgZZN{\XO\|ZXSgZZMheGixc4Doc{1CVEtibHX2[Ywh[W[2ZYKgNUBpeiCkeTDzZY5lf2mlaDDFUGlUSSxiSVO1NEA:KDBwMU[1JO69VS5?	NIPoS3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEixPVEyPid-MkS4NVkyOTZ:L3G+
Function assay	M1j3SW5KUC1\|VEO=		M3Syd\|EhcHJ?		NWO5RWtkUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BEOTF3NmmgcZV1[W62IHX4dJJme3OnZDDpckBud3W\|ZTDOTWguO1R\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IIDoc5NxcG9vQVzLJIxmfmWuIHHmeIVzKDFiaIKgZpkhe2GwZIfpZ4ghTUyLU1GsJGlEPTBiPTCwMlQ4QCEQvF2u	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDhzOUGxOkc,OjR6MUmxNVY9N2F-
Function assay	MnWxUmlJNTOWMx?=		MmnUNUBpeg>?		NG\4WpFKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGcyOjZ7QTDteZRidnRiZYjwdoV{e2WmIHnuJI1wfXOnIF7JTE0{XDNiY3XscJMh[XO\|ZYPz[YQh[XNicHjvd5Bpdy2DTFugcIV3\WxiYX\0[ZIhOSCqcjDifUB{[W6md3njbEBGVEmVQTygTWM2OCB;IECuOlA2KM7:TT6=	M4rVdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEG5NVE3Lz5{NEixPVEyPjxxYU6=
Function assay	NYXyZY1GVkmKLUPUNy=>		MYixJIhz		NVHwb49lUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BUOTJyNmmgcZV1[W62IHX4dJJme3OnZDDpckBud3W\|ZTDOTWguO1R\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IIDoc5NxcG9vQVzLJIxmfmWuIHHmeIVzKDFiaIKgZpkhe2GwZIfpZ4ghTUyLU1GsJGlEPTBiPTCwMlYzPiEQvF2u	M1XPXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEG5NVE3Lz5{NEixPVEyPjxxYU6=
Function assay	M2\FZ25KUC1\|VEO=		M323PFEhcHJ?		MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFyxNVk3VSCvdYThcpQh\XiycnXzd4VlKGmwIH3veZNmKE6LSD2zWFMh[2WubIOgZZN{\XO\|ZXSgZZMheGixc4Doc{1CVEtibHX2[Ywh[W[2ZYKgNUBpeiCkeTDzZY5lf2mlaDDFUGlUSSxiSVO1NEA:KDBwOESzJO69VS5?	NF7BOIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEixPVEyPid-MkS4NVkyOTZ:L3G+
Function assay	M2TCfW5KUC1\|VEO=		M4G3UVEhcHJ?		M3;1WWlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugUFEyPTKUIH31eIFvfCCneIDy[ZN{\WRiaX6gcY92e2ViTlnIMVNVOyClZXzsd{Bie3Onc4Pl[EBieyCyaH;zdIhwNUGOSzDs[ZZmdCCjZoTldkAyKGi{IHL5JJNidmS5aXPoJGVNUVODLDDJR\|UxKD1iMT6wNlYh\|ryPLh?=	NUW0cldNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NVkyOTZpPkK0PFE6OTF4PD;hQi=>
Function assay	NWfqV2pqVkmKLUPUNy=>		M{fyNVEhcHJ?		Mn;0TY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDHNVIxOlJibYX0ZY51KGW6cILld5Nm\CCrbjDtc5V{\SCQSVitN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKGGodHXyJFEhcHJiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSBzLkG0PEDPxE1w	MnyzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MUmxNVYoRjJ2OEG5NVE3RC:jPh?=
Function assay	MUXOTWguO1R\|		MlfINUBpeg>?		M2HpOmlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugNVE2OVSrboOgcZV1[W62IHX4dJJme3OnZDDpckBud3W\|ZTDOTWguO1R\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IIDoc5NxcG9vQVzLJIxmfmWuIHHmeIVzKDFiaIKgZpkhe2GwZIfpZ4ghTUyLU1GsJGlEPTBiPTCzMlA{QSEQvF2u	NW\MTFZ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NVkyOTZpPkK0PFE6OTF4PD;hQi=>
Function assay	NX;3ZnlrVUuQOES1		MmPmNUBpeg>?		MmDVTY5pcWKrdHnvckBw\iClLV3leEBxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gUWtPQDR3IHPlcIx{KGGodHXyJFEhcHJiYomge4V{fGW{bjDicI91fGmwZzygTWM2OCB;IECuNFIh\|ryPLh?=	NFfIeZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFc2OCd-MkS5NFA4PTB:L3G+
Function assay	Mo\yUWtPQDR3		M2izc\|kxKG2rboO=		M2\Db2lvcGmkaYTpc44hd2ZiYz3N[ZQheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJG1MVjh2NTDj[YxteyCjZoTldkA6OCCvaX7zJIJ6KFOjbnT3bYNpNUWOSWPBMEBKSzVyIE2gNE4xOiEQvF2u	M3;GSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwO\|UxLz5{NEmwNFc2ODxxYU6=
Function assay	MlrSb4FzeGG\|IEK5PS=>		MYq5NEBucW6\|		MomzTY5pcWKrdHnvckBw\iCQUF2t[pV{\WRiQVzLJJBpd3OyaH;yfYxifGmxbjCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBpfW2jbjDrZZJx[XNiMkm5JINmdGy\|IHHmeIVzKDlyIH3pcpMh[nliU3Hu[Jdq[2hvRVzJV2EtKEmFNUCgQUAxNjFzIN88UU4>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEe1NEc,OjR7MEC3OVA9N2F-
Cytotoxicity assay	MlGxUmNKNUhzOUmz		NGT3do41QCCqcoO=		MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDF7OUOgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwME[xJO69VS5?	MlnNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC4N\|AoRjJ2OUCwPFMxRC:jPh?=
Cytotoxicity assay	NXvZfmZnVkmKL{PUNy=>		M2PTdVQ5KGi{cx?=		MkC1R5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgUmlJNzOWMzDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5\|NkSg{txONg>?	M1;TTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwPFMxLz5{NEmwNFg{ODxxYU6=
Cytotoxicity assay	NXnSXpFESTV2OR?=		M3fVUlQ5KGi{cx?=		M{LBNGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFQvODh2IN88UU4>	NF:yR2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFg{OCd-MkS5NFA5OzB:L3G+
Cytotoxicity assay	MnvEUmNKNUhzOUe1		NEH1d4E1QCCqcoO=		M2nKb2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KMUm3OUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iNz61OVEh\|ryPLh?=	NYjDR5hURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA5OzBpPkK0PVAxQDNyPD;hQi=>
Antiproliferative assay	NWGxc\|VXTUKFMR?=		M4LJbVczKGi{cx?=		MUHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHPNSXQu[W2ybHnmbYVlKGi3bXHuJGVDSzFiY3XscJMh[W[2ZYKgO\|IhcHK\|LDDJR\|UxKD1iMD6wNFY6KM7:TT6=	NUjYdY1QRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA5OzFpPkK0PVAxQDNzPD;hQi=>
Antiproliferative assay	MnH6T2FTWEGVMkm5		M1fOZlczKGi{cx?=		NYP2OmI1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBCVEtvZHXw[Y5l\W62IHj1cYFvKEuDUmDBV\|I6QSClZXzsd{Bi\nSncjC3NkBpenNuIFnDOVAhRSByLkKg{txONg>?	MofxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC4N\|EoRjJ2OUCwPFMyRC:jPh?=
Antitumor assay	M2rScWJCTjN?	MoDGOVAhdWdxa3e=	NYHrV3NROiC5ZXXrdy=>		NVH1WHQ3SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEWPTEStRWxMKG[3c3nvckBxem:2ZXnuJIFtdG:pcnHmeIVlKGmwIH71[IUhdW:3c3WgZZN{\XO\|ZXSgZZMhfHWvb4Kg[5Jwf3SqIHnubIljcXSrb36gZZQhPTBibXevb4ctKHCxIIHkJIZweiB{IIfl[Yt{KHKnbHH0bZZmKHSxII\lbIlkdGVvdILlZZRm\CClb370do9t	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEizNUc,OjR7MEC4N\|E9N2F-
Antiproliferative assay	MX;FRmMy		MYm3NkBpenN?		NEe4dJJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFXCR\|Eh[2WubIOgZYZ1\XJiN{KgbJJ{NCCLQ{WwJF0hOC5yMkGg{txONg>?	NXWwWIluRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1N\|c2OzBpPkK1OVM4PTNyPD;hQi=>
Antiproliferative assay	M3LwSnNPXTV?		MlLMO\|IhcHK\|		NHvYfJJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPOWVUh[2WubIOgZYZ1\XJiN{KgbJJ{NCCLQ{WwJF0hOC5yMkC0JO69VS5?	NFzNNpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCwOVUzOyd-Mk[wNFU2OjN:L3G+
Antiproliferative assay	NFnNRoVGSkNz		MUS3NkBpenN?		M4n6[WFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRVLDNUBk\WyuczDh[pRmeiB5MjDodpMtKEmFNUCgQUAxNjB{MUig{txONg>?	M1;WfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEC1OVI{Lz5{NkCwOVUzOzxxYU6=
Antiproliferative assay	M{TMWG1MVjR3		NGjjTFk4OiCqcoO=		NH\mN4hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3LUlQ2KGOnbHzzJIFnfGW{IEeyJIhzeyxiSVO1NEA:KDBwMEO4NUDPxE1w	NIfpVno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCwOVUzOyd-Mk[wNFU2OjN:L3G+
Antiproliferative assay	MWfCRWY{N1SSUj3N[ZQ>		MmXrO\|IhcHK\|		NEHI[\|JCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMwXFCULV3leEBk\WyuczDh[pRmeiB5MjDodpMtKEmFNUCgQUAxNjF{N{Sg{txONg>?	NXruU2hsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNFU2OjNpPkK2NFA2PTJ\|PD;hQi=>
Antiproliferative assay	MYDOR2kuUDNzMkK=		MY[3NkBpenN?		NHOy[Y5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGFNUy2mZYDlcoRmdnRiaIXtZY4hVkOLLVizNVIzKGOnbHzzJIFnfGW{IEeyJIhzeyxiSVO1NEA:KDBwMk[xNkDPxE1w	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR5Nke0PUc,OjZ2N{[3OFk9N2F-
Antiproliferative assay	Mlz3UmNKNUh\|MUKy		MmjBO\|IhcHK\|		MlrHRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFMyOjJiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9iTIXtbY5me2OnboSgR4VtdCCYaXHibYxqfHliQYPzZZktKEWFNUCgQUAxNjB\|MjFOwG0v	MlG0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
Function assay	MVPCZU9HOw>?		M2fiTFczKGi{cx?=		NFrybYpKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1NUGOSzCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W\|ZTDCZU9HOyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRUKGG\|c3H5MEBKSzVyIE2gNE4xPTZizszNMi=>	M4rKU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Function assay	MmXwRoEwTjN?		MoO4O\|IhcHK\|		MVrJcohq[mm2aX;uJI9nKHerbHSgeJlx\SCHTVy0MWFNUyBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEYT;GN{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDJR\|UxKD1iMD6wOVYh\|ryPLh?=	MlLIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
Function assay	NYPETpR4SmFxRkO=		NEDTTZc4OiCqcoO=		MWLJcohq[mm2aX;uJI9nKEWPTEStRWxMKFNzMkC2XUBufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRoEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFAvODZ3IN88UU4>	NWj4RXVIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
Function assay	NELme4lD[S:IMx?=		M3LUVVczKGi{cx?=		M4LGN2lvcGmkaYTpc44hd2ZiRV3MOE1CVEtiRkGxO\|RNKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBD[S:IMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCLQ{WwJF0hOC5yOEGg{txONg>?	M{HrWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Function assay	NYnGVpF3SmFxRkO=		MWK3NkBpenN?		MoHNTY5pcWKrdHnvckBw\iCHTVy0MWFNUyCFMUG1OnkhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKG2xdYPlJGJiN0Z\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFNiYYPzZZktKEmFNUCgQUAxNjF2NDFOwG0v	M1Hqb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Antiproliferative assay	MYfTUXMuU0OQUh?=		NWS0dnE6PzJiaILz		NWXPSpVJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTUXMuU0OQUjDj[YxteyCneIDy[ZN{cW6pIFXNUFQuSUyNIGKxNlc2WSCvdYThcpQh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9iTIXtbY5me2OnboSgR4VtdCCYaXHibYxqfHliQYPzZZktKEWFNUCgQUAxNjF5OTFOwG0v	MoDKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
Antiproliferative assay	M4PWdmtmdGy7		NVnHb5IyPzJiaILz		MnSwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCNZXzsfUBk\WyuczDlfJBz\XO\|aX7nJGVOVDRvQVzLJGYyOTd2TDDteZRidnRiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gUJVucW6nc3PlcpQhS2WubDDWbYFjcWyrdImgRZN{[XluIFXDOVAhRSByLkKxNUDPxE1w	NVHKSVE1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
Antiproliferative assay	NGDBWJhNSU53		MXq3NkBpenN?		NFPhcFZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFzBUlUh[2WubIOg[ZhxemW\|c3nu[{BGVUx2LVHMT{BTOTJ5NWGgcZV1[W62IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJGx2dWmwZYPj[Y51KEOnbHygWoli[mmuaYT5JGF{e2G7LDDFR\|UxKD1iMD6yN\|Ih\|ryPLh?=	NFnsVI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
Antiproliferative assay	MY\ESmNKPzZ?		NECzXXY4OiCqcoO=		MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESIQ1m3OkBk\WyuczDlfJBz\XO\|aX7nJGVOVDRvQVzLJGwyOTV{UjDteZRidnRiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gUJVucW6nc3PlcpQhS2WubDDWbYFjcWyrdImgRZN{[XluIFXDOVAhRSByLkKzN{DPxE1w	M4DoNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Function assay	NGG1UGdD[S:IMx?=		NIXLeXI4OiCqcoO=		MkDuTY5pcWKrdHnvckBw\iCHTVy0MWFNUyCJMUKwNnIhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKG2xdYPlJGJiN0Z\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFNiYYPzZZktKEmFNUCgQUAxNjN{ODFOwG0v	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Antiproliferative assay	MlzkV2suVi2VSB?=		Mnf0O\|IhcHK\|		MV7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONLV6tV2gh[2WubIOg[ZhxemW\|c3nu[{BGVUx2LVHMT{BHOTF5NFygcZV1[W62IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJGx2dWmwZYPj[Y51KEOnbHygWoli[mmuaYT5JGF{e2G7LDDFR\|UxKD1iMD6zO{DPxE1w	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Antiproliferative assay	M1zuUGNJVEF{MB?=		NEnBfmM4OiCqcoO=		MXvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEOKTFGyNEBk\WyuczDlfJBz\XO\|aX7nJGVOVDRvQVzLJHIyOjd3UTDteZRidnRiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gUJVucW6nc3PlcpQhS2WubDDWbYFjcWyrdImgRZN{[XluIFXDOVAhRSByLkSzPUDPxE1w	Mmq3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
Function assay	Mlu0RoEwTjN?		MoflO\|IhcHK\|		Mn;QTY5pcWKrdHnvckBw\iCHTVy0MWFNUyCJMUK2PWEhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKG2xdYPlJGJiN0Z\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFNiYYPzZZktKEmFNUCgQUAxNjVzMjFOwG0v	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Antiproliferative assay	MWfTTE1UYTW\		NYrOR4pHPzJiaILz		MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOKLWPZOXkh[2WubIOg[ZhxemW\|c3nu[{BGVUx2LVHMT{BHOTF5NFygcZV1[W62IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJGx2dWmwZYPj[Y51KEOnbHygWoli[mmuaYT5JGF{e2G7LDDFR\|UxKD1iMD61NlMh\|ryPLh?=	M4fZNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Function assay	NHHr[YZD[S:IMx?=		MWq3NkBpenN?		NYqwcolrUW6qaXLpeIlwdiCxZjDFUWw1NUGOSzDMNVE6Pk1ibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKjL1[zJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSByLkW0PUDPxE1w	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Function assay	M3XIRWJiN0Z\|		NHf5Tmk4OiCqcoO=		MUDJcohq[mm2aX;uJI9nKEWPTEStRWxMKExzMUWyVkBufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRoEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFAvPjR3IN88UU4>	MlfHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
Antiproliferative assay	MVPTT{1PNUKHKEKp		M135UFczKGi{cx?=		NVvRcYg4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT{1PNUKHKEKpJINmdGy\|IHX4dJJme3Orbnege4lt\CC2eYDlJGVOVDRvQVzLJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKEy3bXnu[ZNk\W62IFPlcIwhXmmjYnnsbZR6KEG\|c3H5MEBGSzVyIE2gNE44OSEQvF2u	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Function assay	M3;kPGJiN0Z\|		M17W[lczKGi{cx?=		MX7Jcohq[mm2aX;uJI9nKEWPTEStRWxMKDFzNUHUbY5{KG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBD[S:IMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCLQ{WwJF0hOC56NUeg{txONg>?	NWX5UYtRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
Cytotoxicity assay	M1XvZWJCN0Z\|		NH\DcVA4OiCqcoO=		MVPDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRUKGG\|c3H5MEBKSzVyIE2gNE46OjdizszNMi=>	NEO5UFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
Antiproliferative assay	Mm\QUGFPOQ>?		NXz3SI5NPzJiaILz		Ml:wRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCOQV6xJINmdGy\|IHX4dJJme3OrbnegSW1NPC2DTFugSlEyPzSOIH31eIFvfCCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDMeY1qdmW\|Y3XueEBE\WyuIG\pZYJqdGm2eTDBd5NigSxiRVO1NEA:KDFwM{S2JO69VS5?	Mk\6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
Antiproliferative assay	NGrURWtUUy2QLV\J		NWnaU\|BFPzJiaILz		NVLy[WVISW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT{1PNU[LIHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFXNUFQuSUyNIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJGx2dWmwZYPj[Y51KEOnbHygWoli[mmuaYT5JGF{e2G7LDDFR\|UxKD1iMT60Olkh\|ryPLh?=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Antiproliferative assay	MYXTT{1PNUGV		MXG3NkBpenN?		M3zKTWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utUk1CWyClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCHTVy0MWFNUyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDMeY1qdmW\|Y3XueEBE\WyuIG\pZYJqdGm2eTDBd5NigSxiRVO1NEA:KDFwNEezJO69VS5?	M1vwd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Antiproliferative assay	Mo\mSGZEUTFzNB?=		NUXLV4FbPzJiaILz		NH;NfoRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTGR2kyOTRiY3XscJMh\XiycnXzd4lv\yCHTVy0MWFNUyCJMUK2PWEhdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKEy3bXnu[ZNk\W62IFPlcIwhXmmjYnnsbZR6KEG\|c3H5MEBGSzVyIE2gNU43OTVizszNMi=>	NFTJTnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
Antiproliferative assay	MXLFRmMy		NVLE[G9GPzJiaILz		MmjzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCHQlOxJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFnDOVAhRSByLkCxPUDPxE1w	M1;h[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Nkm4OVM3Lz5{Nk[5PFU{PjxxYU6=
Cytotoxicity assay	NXL4Z4toTUKFMR?=		NYizUoN3PzJiaILz		NIT6cINEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBGSkNzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGGodHXyJFczKGi{czDifUB{fWyob4Loc4RidWmwZTDCJIF{e2G7LDDJR\|UxKD1iMD6wOFQh\|ryPLh?=	M4LzdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEG3OVQ5Lz5{N{CxO\|U1QDxxYU6=
Antiproliferative assay	NWfYNIVKU0GUUFHTNlk6		Mmf3O\|IhcHK\|		Mo[xRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCNQWLQRXMzQTliY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHNTSi:FQ1utPEBie3OjeTygTWM2OCB;IECuNVA{KM7:TT6=	M{W3[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUOxNFY3Lz5{N{GzNVA3PjxxYU6=
Antiproliferative assay	NWTBR\|hqW1WSLV2y		NUXJb\|ZEPzJiaILz		M{CxbmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2XQMW0zKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIwS0ONLUigZZN{[XluIFnDOVAhRSByLkGxNkDPxE1w	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF\|MUC2Okc,OjdzM{GwOlY9N2F-
Antiproliferative assay	MVPTWU1FUExz		Mk\aO\|IhcHK\|		M3L0Z2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2WtSGhNOSClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDN0OFSz24JIF{e2G7LDDJR\|UxKD1iMD6xN\|Yh\|ryPLh?=	MknHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{GwOlYoRjJ5MUOxNFY3RC:jPh?=
Antiproliferative assay	NXrFTIZCVkOLLVizNVIz		NEDuW3Y4OiCqcoO=		NWHtPI95SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDNzMkKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQj;DR2suQCCjc4PhfUwhUUN3MDC9JFAvOjFizszNMi=>	M2LvT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUOxNFY3Lz5{N{GzNVA3PjxxYU6=
Function assay	MWPOR2kuUDNzMkK=		MXu3NkBpenN?		MmWyTY5pcWKrdHnvckBw\iCDTFug[ZhxemW\|c3XkJIlvKGi3bXHuJG5EUS2KM{GyNkBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCVUlKvR2NMNThiYYPzZZktKEmFNUCgQUAxNjJ4MTFOwG0v	M{Cy[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUOxNFY3Lz5{N{GzNVA3PjxxYU6=
Antiproliferative assay	NFrH[ZpPUUhxM2Sz		NXO5fFd5PzJiaILz		NXizPXFJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDOTWgwO1R\|IHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFXNUFQuSUyNIHHmeIVzKDd{IHjyd{BjgSCVUlKvR2NMNThiYYPzZZktKEmFNUCgQUAxNjJ6MzFOwG0v	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF\|MUC2Okc,OjdzM{GwOlY9N2F-
Antiproliferative assay	NWn6UohPVkmKL{PUNy=>		NV\SO5A2PzJiaILz		MV;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKE6LSD:zWFMh[2WubIOg[ZhxemW\|c3nu[{BGVUx2LVHMT{BNOTF7NjDteZRidnRiYX\0[ZIhPzJiaILzJIJ6KFOUQj;DR2suQCCjc4PhfUwhUUN3MDC9JFEvOTZizszNMi=>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF\|MUC2Okc,OjdzM{GwOlY9N2F-
Antiproliferative assay	M4XBPGFNUy2yb4PpeIl3\SCNQWLQRXMzQTl?		NUP0O5pzPzJiaILz		M2HmNWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQVzLMZBwe2m2aY\lJGtCWlCDU{K5PUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkhdWWjc4Xy[YQh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldkA6PiCjcYXlc5V{KG:wZTDzc4x2fGmxbjDj[YxtKHC{b3zp[oVz[XSrb36gZZN{[XluIFnDOVAhRSByLkO2OUDPxE1w	NX;5NHAyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexOFQ5OzFpPkK3NVQ1QDNzPD;hQi=>
Antiproliferative assay	MWHBUGsudmWpYYTpeoUhXTl\|Nx?=		NVHt[nh5PzJiaILz		M3j2ZWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQVzLMY5m\2G2aY\lJHU6OzdiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IH3lZZN2emWmIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJiOU[gZZF2\W:3czDvcoUhe2:udYTpc44h[2WubDDwdo9tcW[ncnH0bY9vKGG\|c3H5MEBKSzVyIE2gNk4zQDZizszNMi=>	M4X6flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUS0PFMyLz5{N{G0OFg{OTxxYU6=
Cytotoxicity assay	M{XrW2hmeEd{		NWHpSlczPzJiaILz		Mke3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDNwNzFOwG0v	MnPTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd\|OU[5NlkoRjJ5M{m2PVI6RC:jPh?=
Cytotoxicity assay	MX\NTWFR[UOjMh?=		M3TFeVczKGi{cx?=		M1:0RWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1KSVCjQ3GyJINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC3MlE3KM7:TT6=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzN7NkmyPUc,Ojd\|OU[5Nlk9N2F-
Cytotoxicity assay	NEG4SHBJS0N6Mke=		NGm2U484OiCqcoO=		M2Pn[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhESzh{NzDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iNz6yOUDPxE1w	M3nDPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5M{m2PVI6Lz5{N{O5OlkzQTxxYU6=
Cytotoxicity assay	MXXLRXJRSVN{OUm=		MYC3NkBpenN?		NG\NZWlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMSVKSQWOyPVkh[2WubIOgbIFz[m:{aX7nJG5RVS2DTFugZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6wOlgh\|ryPLh?=	NIPPSHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{S3OFkzPSd-Mke0O\|Q6OjV:L3G+
Cytotoxicity assay	M4f6c2hESzd6		MWO3NkBpenN?		M1LtdGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhESzd6IHPlcIx{KGijcnLvdolv\yCVTFOzOGEzNVKRU{GgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6zOEDPxE1w	NHXsN\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{S3OFkzPSd-Mke0O\|Q6OjV:L3G+
Antiproliferative assay	NXTzPXBRW1VvRFjMNS=>		MmLPO\|IhcHK\|		NE\ocGlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGFNUyClb37zeIl1fXSrdnXsfUBi[3SrdnH0[YQhcHWvYX6gV3UuTEiOMTDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIH;yJGNEUzhiYYPzZZktKEmFNUCgQUAxNjB7MkOg{txONg>?	NGezVlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e2PVYzOyd-Mke3Olk3OjN:L3G+
Antiproliferative assay	MXnOR2kuUDNzMkK=		NGrVNY84OiCqcoO=		M1GwXWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgRWxMKGOxboP0bZR2fGm4ZXz5JIFkfGm4YYTl[EBpfW2jbjDOR2kuUDNzMkKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQjDvdkBES0t6IHHzd4F6NCCLQ{WwJF0hOC5zMEC5JO69VS5?	MoDFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5Nkm2NlMoRjJ5N{[5OlI{RC:jPh?=
Antiproliferative assay	NXqzeVNPU0GUUFHTNlk6		MoXzO\|IhcHK\|		M4\ObWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgRWxMKGOxboP0bZR2fGm4ZXz5JIFkfGm4YYTl[EBpfW2jbjDLRXJRSVN{OUmgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQjDvdkBES0t6IHHzd4F6NCCLQ{WwJF0hOC5zMES5JO69VS5?	NVHxfJVYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3Olk3OjNpPkK3O\|Y6PjJ\|PD;hQi=>
Function assay	NX3YW45zVkmKL{PUNy=>				M3\qTGlvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFXNUFQwSUyNIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJG5KUC9\|VEOgZ4VtdHNuIFnDOVAhRSByLkC4JO69VS5?	M1HMc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOxN\|QxLz5{OESzNVM1ODxxYU6=
Function assay	M{O3Om5KUC9\|VEO=				Ml;sTY5pcWKrdHnvckBw\iC5aXzkJJR6eGViRV3MOE9CVEtiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gUmlJNzOWMzDj[YxteyxiSVO1NEA:KDBwMEig{txONg>?	MmLmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2M{GzOFAoRjJ6NEOxN\|QxRC:jPh?=
Function assay	M1fvZ25KUC9\|VEO=				MUnJcohq[mm2aX;uJI9nKHerbHSgeJlx\SCHTVy0M2FNUyCIMUG3OGwhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKE6LSD:zWFMh[2WubIOsJGlEPTBiPTCwMlE3PSEQvF2u	NWX4TJZERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0N\|E{PDBpPkK4OFMyOzRyPD;hQi=>
Function assay	MXjOTWgwO1R\|				NIC5N3pKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzDGNVE4PExibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIF7JTE8{XDNiY3XscJMtKEmFNUCgQUAxNjF4NTFOwG0v	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR\|MUO0NEc,Ojh2M{GzOFA9N2F-
Function assay	MlXpUmlJNzOWMx?=				NYW3W4lyUW6qaXLpeIlwdiCxZjD3bYxlKHS7cHWgSW1NPC:DTFugR\|EyPT[\IH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDOTWgwO1R\|IHPlcIx{NCCLQ{WwJF0hOC52N{ig{txONg>?	Mn;6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2M{GzOFAoRjJ6NEOxN\|QxRC:jPh?=
Function assay	NUK3S24zVkmKL{PUNy=>				NXnWW2l[UW6qaXLpeIlwdiCxZjD3bYxlKHS7cHWgSW1NPC:DTFugR\|EyPT[\IH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDOTWgwO1R\|IHPlcIx{NCCLQ{WwJF0hOC52N{ig{txONg>?	NFrzN489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzNVM1OCd-Mki0N\|E{PDB:L3G+
Function assay	MlThUmlJNzOWMx?=				MW\Jcohq[mm2aX;uJI9nKHerbHSgeJlx\SCHTVy0M2FNUyCJMUK2PWEhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKE6LSD:zWFMh[2WubIOsJGlEPTBiPTCwMlYxPSEQvF2u	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR\|MUO0NEc,Ojh2M{GzOFA9N2F-
Function assay	NVHnbItKVkmKL{PUNy=>				Ml\MTY5pcWKrdHnvckBw\iC5aXzkJJR6eGViRV3MOE9CVEtiR{GyOllCKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCQSVivN3Q{KGOnbHzzMEBKSzVyIE2gNE43ODVizszNMi=>	NUDZb\|NKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0N\|E{PDBpPkK4OFMyOzRyPD;hQi=>
Function assay	NFTT[IFPUUhxM2Sz				M2HRdWlvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFXNUFQwSUyNIGOxNlA3YSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iTlnIM\|NVOyClZXzsd{whUUN3MDC9JFAvPjJ4IN88UU4>	M{GyNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOxN\|QxLz5{OESzNVM1ODxxYU6=
Function assay	NV;0UG15VkmKL{PUNy=>				MU\Jcohq[mm2aX;uJI9nKHerbHSgeJlx\SCHTVy0M2FNUyCVMUKwOnkhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKE6LSD:zWFMh[2WubIOsJGlEPTBiPTCwMlYzPiEQvF2u	NWjnSmJlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0N\|E{PDBpPkK4OFMyOzRyPD;hQi=>
Function assay	NUDkOnRiVkmKL{PUNy=>				MXLJcohq[mm2aX;uJI9nKHerbHSgeJlx\SCHTVy0M2FNUyCOMUG5Om0hdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKE6LSD:zWFMh[2WubIOsJGlEPTBiPTCwMlg1OyEQvF2u	MlPKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2M{GzOFAoRjJ6NEOxN\|QxRC:jPh?=
Function assay	MkHWUmlJNzOWMx?=				NUfBVFRZUW6qaXLpeIlwdiCxZjD3bYxlKHS7cHWgSW1NPC:DTFugUFEyQT[PIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDOTWgwO1R\|IHPlcIx{NCCLQ{WwJF0hOC56NEOg{txONg>?	NXzqT\|l2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0N\|E{PDBpPkK4OFMyOzRyPD;hQi=>
Function assay	MUTOTWgwO1R\|				M3z1NWlvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFXNUFQwSUyNIFyxNVUzWiCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iTlnIM\|NVOyClZXzsd{whUUN3MDC9JFEvODJ4IN88UU4>	MojpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2M{GzOFAoRjJ6NEOxN\|QxRC:jPh?=
Function assay	MY\OTWgwO1R\|				M1Htc2lvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFXNUFQwSUyNIFyxNVUzWiCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iTlnIM\|NVOyClZXzsd{whUUN3MDC9JFEvODJ4IN88UU4>	NInoV\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzNVM1OCd-Mki0N\|E{PDB:L3G+
Function assay	MWfOTWgwO1R\|				MlzXTY5pcWKrdHnvckBw\iC5aXzkJJR6eGViRV3MOE9CVEtiR{GyNFJTKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCQSVivN3Q{KGOnbHzzMEBKSzVyIE2gNU4yPDhizszNMi=>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR\|MUO0NEc,Ojh2M{GzOFA9N2F-
Function assay	NXjncIJPVkmKL{PUNy=>				NFW4PWRKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzDHNVIxOlJibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIF7JTE8{XDNiY3XscJMtKEmFNUCgQUAyNjF2ODFOwG0v	Mkf2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2M{GzOFAoRjJ6NEOxN\|QxRC:jPh?=
Function assay	MmLNUmlJNzOWMx?=				NGHUb45KdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzCxNVUyXGmwczDteZRidnRiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gUmlJNzOWMzDj[YxteyxiSVO1NEA:KDNwMEO5JO69VS5?	M3LwVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOxN\|QxLz5{OESzNVM1ODxxYU6=
Function assay	NELi[ldPUUhxM2Sz				MXjJcohq[mm2aX;uJI9nKHerbHSgeJlx\SCHTVy0M2FNUyBzMUWxWIlveyCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iTlnIM\|NVOyClZXzsd{whUUN3MDC9JFMvODN7IN88UU4>	NX\ObXNqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0N\|E{PDBpPkK4OFMyOzRyPD;hQi=>
Cytotoxicity assay	MojCSWJEOQ>?		M33iPVczKGi{cx?=		NH3oUFVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBGSkNzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCFZXzsJHRqfGW{LVfsc{Bie3OjeTygRYN1cX[rdImgQUAxNjBzMzFOwG0v	M13pSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{W1OlM2Lz5{OEe1OVY{PTxxYU6=
Cytotoxicity assay	NXP3O5h5VUuQNEW=		NEjoUpc4OiCqcoO=		MXXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNT241PSClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhS2WubDDUbZRmei2JbH:gZZN{[XluIFHjeIl3cXS7IE2gNE4xOjJizszNMi=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDd3NU[zOUc,Ojh5NUW2N\|U9N2F-
Cytotoxicity assay	MoL6VGM{		MWm3NkBpenN?		MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR\|Mh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGxiVHn0[ZIuT2yxIHHzd4F6NCCDY4Tpeol1gSB;IEKuNlQ1KM7:TT6=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDd3NU[zOUc,Ojh5NUW2N\|U9N2F-
Function assay	NFz6VW9DSUZ\|		M3q5cFczKGi{cx?=		MlvDTY5pcWKrdHnvckBw\iCHTVy0MYZ2e2WmIFHMT{ApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBDSUZ\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJINmdGxicILvcIln\XKjdHnvckBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFAvODByMzFOwG0v	NUm0cVN3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVA6OjJpPkK4PFUxQTJ{PD;hQi=>
Function assay	NVTjcGNbSkGIMx?=		NUjiPFNIPzJiaILz		MoPUTY5pcWKrdHnvckBw\iCQUF2t[pV{\WRiQVzLJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKG2xdYPlJGJCTjNiY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBIUTVyIE2gNE4xODB\|IN88UU4>	Mn63QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUC5NlIoRjJ6OEWwPVIzRC:jPh?=
Function assay	M2nyUGJCTjN?		M1PLd\|czKGi{cx?=		MlnWTY5pcWKrdHnvckBw\iCWRVyt[pV{\WRiQVzLJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKG2xdYPlJGJCTjNiY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBIUTVyIE2gNE4xODB\|IN88UU4>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3MEmyNkc,Ojh6NUC5NlI9N2F-
Antiproliferative assay	NVWxb2JoVkOLLVizNVIz		M{XJZVczKGi{cx?=		MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IN\|EzOiClZXzsd{Bp[XKkb4LpcochTU2OND3meZNm\CCDTFugeoFzcWGwMTDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygS2k2OCB;IECuNFM4KM7:TT6=	NEj6VGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1NFkzOid-Mki4OVA6OjJ:L3G+
Antiproliferative assay	NEf3WZNPS0lvSEKyNlg>		MnHmO\|IhcHK\|		Ml3iRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFIzOjhiY3XscJMhcGG{Yn;ybY5oKEWPTESt[pV{\WRiQVzLJJZiemmjbkOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYmsJGdKPTBiPTCwMlA4OyEQvF2u	MoTEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUC5NlIoRjJ6OEWwPVIzRC:jPh?=
Function assay	MUTCRWY{		Mn3NO\|IhcHK\|		M3TxW2lvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIFHMT{BEOTF3NmmgcZV1[W62IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLBSlMh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDHTVUxKD1iMD6xOUDPxE1w	NULMeJpVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVA6OjJpPkK4PFUxQTJ{PD;hQi=>
Function assay	NYXqcIw1SkGIMx?=		MmrXO\|IhcHK\|		MnHGTY5pcWKrdHnvckBw\iCodXzsJIxmdme2aDDBUGshTjFzN{TMJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W\|ZTDCRWY{KGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygS2k2OCB;IECuN\|Ih\|ryPLh?=	NGnje\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1NFkzOid-Mki4OVA6OjJ:L3G+
Function assay	NXrNfoZzSkGIMx?=		Mne1O\|IhcHK\|		MUDJcohq[mm2aX;uJI9nKFSHTD3meZNm\CCDTFugS\|EzODKUIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEQV[zJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiR1m1NEA:KDBwNEOg{txONg>?	MnyxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUC5NlIoRjJ6OEWwPVIzRC:jPh?=
Antiproliferative assay	NFjiU5dEUEx?		MnvvO\|IhcHK\|		MkH5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDDTGwh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYmsJGdKPTBiPTCwMlQ2KM7:TT6=	MmHTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUC5NlIoRjJ6OEWwPVIzRC:jPh?=
Function assay	MYXCRWY{		NVjaelBqPzJiaILz		NVTFTZhGUW6qaXLpeIlwdiCxZjDUSWwu\nW\|ZXSgRWxMKExzMUm2UUBufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRmFHOyClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYmsJGdKPTBiPTCwMlU6KM7:TT6=	M13HcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWwPVIzLz5{OEi1NFkzOjxxYU6=
Antiproliferative assay	MnPlRmFHOw>?		NHjiW2s4OiCqcoO=		M1nEXGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlHGN{Bk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygS2k2OCB;IEGuNUDPxE1w	NFjzNWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1NFkzOid-Mki4OVA6OjJ:L3G+
Antiproliferative assay	NYTuV5NFS0iR		MlvhO\|IhcHK\|		NIH1ZlJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGNJVyClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFMvOiEQvF2u	MkHCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUC5NlIoRjJ6OEWwPVIzRC:jPh?=
Antiproliferative assay	NGHQSY5PS0lvSEKyNlg>		NXjzd4M2PzJiaILz		MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3INlIzQCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNk42KM7:TT6=	NUHK[XhtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmwPVE1OjVpPkK5NFkyPDJ3PD;hQi=>
Antiproliferative assay	NXv3d21LUDJ{MkivR3I>		NELWWHo4OiCqcoO=		MkPxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKMkKyPE9EWiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNVAh\|ryPLh?=	M{j1NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MEmxOFI2Lz5{OUC5NVQzPTxxYU6=
Function assay	MmL0TFIzOjh?	MkfGNE42KHWP	NXq5No9pOyCqcoO=		MUHJcohq[mm2aX;uJI9nKEGOSzDpckBpfW2jbjDINlIzQCClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDBT3QheGixc4Doc5J6dGG2aX;uJIF1KDBwNTD1UUBi\nSncjCzJIhzeyCkeTDX[ZN1\XKwIHLsc5QhdWW2aH;k	MoriQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlyOUG0NlUoRjJ7MEmxOFI2RC:jPh?=
Function assay	M3vnPGJiN0Z\|	M{nGUFAvOSC2bzCxJJVO	MXS3NkBpenN?		M4LMNGlvcGmkaYTpc44hd2ZiaIXtZY4hf2muZDD0fZBmKEWPTESg[pV{\WRiQVzLJIV5eHKnc4Pl[EBqdiCvb4Xz[UBD[S:IMzDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBk\WyuIIDyc4xq\mW{YYTpc44h[XRiMD6xJJRwKDFidV2gdJJmcW6ldXLheIVlKG[xcjC3NkBpenNiZn;scI94\WRiYomgcYV1cHmuLUPIMZRpgW2rZHnu[UBqdmOxcoDvdoF1cW:wIH3lZZN2emWmIHHmeIVzKDhiaILzJIJ6KG[rbITldkB{[2mwdHnscIF1cW:wIHPveY51\Q>?	NV7ZT4UzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmwPVE1OjVpPkK5NFkyPDJ3PD;hQi=>
Antiproliferative assay	M12wXGtCWlCDU{K5PS=>		MkDjO\|IhcHK\|		NHv3N4JCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvBVnBCWzJ7OTDj[YxteyCqYYLic5JqdmdiTmDNMWFNUyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5yOEeg{txONg>?	MlvSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzN{S4NFkoRjJ7MUe0PFA6RC:jPh?=
Antiproliferative assay	MVPIR2M4QA>?		MUS3NkBpenN?		MmPoRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ1O3PEBk\WyuczDoZZJjd3KrbnegV2xEOzSDMj3SU3MyKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjF5IN88UU4>	NI\YUok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG3OFgxQSd-MkmxO\|Q5ODl:L3G+
Antiproliferative assay	Ml7CUmNKNUh{MkK4		NVnrWI14PzJiaILz		NVKxfWxqSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDJ{MkigZ4VtdHNiaHHyZo9zcW6pIFXNUFQuSUyNIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkK0JO69VS5?	MkjKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzN{S4NFkoRjJ7MUe0PFA6RC:jPh?=
Antiproliferative assay	MlvaUmNKNUh\|MUKy		MX:0PEBpenN?		NH3XT5BCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOzF{MjDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC56IN88UU4>	NHPve2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG3OFgyPCd-MkmxO\|Q5OTR:L3G+
Antiproliferative assay	MVrIR2M4QA>?		Mlj5OFghcHK\|		M3v0fWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPDO\|gh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEKg{txONg>?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF5NEixOEc,OjlzN{S4NVQ9N2F-
Antiproliferative assay	MWDFRmMy		M3z2SlczKGi{cx?=		MXXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEWEQ{GgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEGuYX3hdoJtfWViYYPzZZktKEmFNUCgQUAxNjBzMzFOwG0v	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJyMkSxNEc,Ojl{MEK0NVA9N2F-
Antiproliferative assay	NEHUUppOU052NR?=		NEDTfVQ4OiCqcoO=		NI\2SGxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3LUlQ2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDBcIFu[XKkbIXlJIF{e2G7LDDJR\|UxKD1iMD6wNlIh\|ryPLh?=	M1m2V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MkCyOFExLz5{OUKwNlQyODxxYU6=
Antiproliferative assay	M2\YPW1ETjd?		MYO3NkBpenN?		NIj6cXRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFHsZY1iemKudXWgZZN{[XlicnXsZZRqfmVidH:gZ49vfHKxbDygTWM2OCB;IECuNFQ2KM7:TT6=	M3jiR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MkCyOFExLz5{OUKwNlQyODxxYU6=
Antiproliferative assay	MVvBOVQ6		NVHCZXBiPzJiaILz		NIqzV2NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFHsZY1iemKudXWgZZN{[XlicnXsZZRqfmVidH:gZ49vfHKxbDygTWM2OCB;IECuNVM1OyEQvF2u	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJyMkSxNEc,Ojl{MEK0NVA9N2F-
Antiproliferative assay	NXvpNZFoUEOWMUG2		M{e1WFczKGi{cx?=		NIPrdHFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjC3NkBpenNiYomgRYxidWG{Ynz1[UBie3OjeTDy[YxifGm4ZTD0c{Bkd262cn;sMEBKSzVyIE2gNE4zPTN4IN88UU4>	NEDlcFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUKwNlQyOCd-MkmyNFI1OTB:L3G+
Antiproliferative assay	MWTTS2M4QTBz		M2DQT\|czKGi{cx?=		NELoVpVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPHR\|c6ODFiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGFt[W2jcnLseYUh[XO\|YYmgdoVt[XSrdnWgeI8h[2:wdILvcEwhUUN3MDC9JFAvOzJzMzFOwG0v	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJyMkSxNEc,Ojl{MEK0NVA9N2F-
Antiproliferative assay	MXrOR2kuUDR4MB?=		NYjheY42PzJiaILz		M1vZOGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg1PjBiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGFt[W2jcnLseYUh[XO\|YYmsJGlEPTBiPTCyMlI1PCEQvF2u	MnvYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{MEK0NVAoRjJ7MkCyOFExRC:jPh?=
Antiproliferative assay	NIHIR25EV0yRMkC1		MXK3NkBpenN?		MXrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEORTF:yNFUh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFHsZY1iemKudXWgZZN{[XluIFnDOVAhRSB{LkS0PUDPxE1w	NI\H[4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUKwNlQyOCd-MkmyNFI1OTB:L3G+
Antiproliferative assay	MkW5VGM{		NUjiS4xQPzJiaILz		NH;UVHlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczDh[pRmeiB5MjDodpMh[nliQXzhcYFz[my3ZTDhd5NigSxiSVO1NEA:KDlwN{i3JO69VS5?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJyMkSxNEc,Ojl{MEK0NVA9N2F-
Antiproliferative assay	M3Tae2JCTjN?		MoKzO\|IhcHK\|		MnXHRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQV[zJINmdGy\|IHjhdoJwemmwZzDDSFc1NVKRU{GgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBweiCFQ1u4JIF{e2G7LDDJR\|UxKD1iMD6wOFg3KM7:TT6=	Ml7FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{OEi5OFAoRjJ7Mki4PVQxRC:jPh?=
Antiproliferative assay	MUTCRWY{		M4jPelczKGi{cx?=		MX3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNiaHHyZo9zcW6pIFXNUFQuSUyNIHHmeIVzKDd{IHjyd{BjgSCVUlKgc5IhS0ONODDhd5NigSxiSVO1NEA:KDBwMEW3OUDPxE1w	NYrXWpdrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFg6PDBpPkK5Nlg5QTRyPD;hQi=>
Antiproliferative assay	NX\HNG9pW1VvRFjMNS=>		NF:2dYE4OiCqcoO=		MWPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOXLVTIUFEh[2WubIOgbIFz[m:{aX7nJG5RVS2DTFugZYZ1\XJiN{KgbJJ{KGK7IGPSRkBweiCFQ1u4JIF{e2G7LDDJR\|UxKD1iMD6xOVUh\|ryPLh?=	NGHPRpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
Antiproliferative assay	MoK5T2FTWEGVMkm5		MYi3NkBpenN?		NU\DT2pnSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLRXJRSVN{OUmgZ4VtdHNiaHHyZo9zcW6pIF7QUU1CVEtiYX\0[ZIhPzJiaILzJIJ6KFOUQjDvdkBES0t6IHHzd4F6NCCLQ{WwJF0hOC5zN{[g{txONg>?	NFHaWok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
Antiproliferative assay	M{LmNG5EUS2KM{GyNi=>		NXqwc2lvPzJiaILz		M4fKW2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGGodHXyJFczKGi{czDifUBUWkJib4KgR2NMQCCjc4PhfUwhUUN3MDC9JFAvOzB\|IN88UU4>	M3TsWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Mki4PVQxLz5{OUK4PFk1ODxxYU6=
Antiproliferative assay	NHXEWWpDSUZ\|		NHPBflQ4OiCqcoO=		M1zDbmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlHGN{Bk\WyuczDoZZJjd3KrbnegSW1NPC2DTFugUFEyQT[PIH31eIFvfCCjZoTldkA4OiCqcoOgZpkhW1KEIH;yJGNEUzhiYYPzZZktKEmFNUCgQUAxNjN2IN88UU4>	NH\6VZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
Antiproliferative assay	NVG2Z3F[SkGIMx?=		MoHMO\|IhcHK\|		NVrBdYNRSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIhiemKxcnnu[{BGVUx2LVHMT{BIOTJyMmKgcZV1[W62IHHmeIVzKDd{IHjyd{BjgSCVUlKgc5IhS0ONODDhd5NigSxiSVO1NEA:KDBwNU[0JO69VS5?	M13nNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Mki4PVQxLz5{OUK4PFk1ODxxYU6=
Antiproliferative assay	NH3GeGhDSUZ\|		NIXGPVY4OiCqcoO=		MUnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNiaHHyZo9zcW6pIFPEO\|QuWk:VMTDHNlA{OlJibYX0ZY51KGGodHXyJFczKGi{czDifUBUWkJib4KgR2NMQCCjc4PhfUwhUUN3MDC9JFAvPTl2IN88UU4>	M3LtNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Mki4PVQxLz5{OUK4PFk1ODxxYU6=
Antiproliferative assay	M1;YXmJCTjN?		NIrkWYo4OiCqcoO=		NV\2ZpJFSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBKVDNvc4TpcZVt[XSnZDDtc5V{\SCEQV[zJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCVUlKgc5IhS0ONODDhd5NigSxiSVO1NEA:KDBwNkS0JO69VS5?	NHnsT2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
Antiproliferative assay	M2LyUWhESzd6		M{PiSFczKGi{cx?=		NXH4XZQ{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR2M4QCClZXzsd{Bp[XKkb4LpcochW0yFM{TBNk1TV1NzIHHmeIVzKDd{IHjyd{BjgSCVUlKgc5IhS0ONODDhd5NigSxiSVO1NEA:KDBwOEi5JO69VS5?	M3X2WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Mki4PVQxLz5{OUK4PFk1ODxxYU6=
qHTS assay	MmniWGM{Og>?				MYrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXEN\|MjDj[Yxtew>?	M17OXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	MnvERVY4Ow>?				Mn7GdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN?	M4DwOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	M1;xcnNid3NvMh?=				NVTJOHd4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	M3jMTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	MnO4VmQ>				MnvXdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{	NYPafYFpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	MYnTT{1PNVOK				M{nEOpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz	M4\jdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	MX;CWE0yOg>?				NHe3XIdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO=	NXi5cXdURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	MV\NS{A3OyBqNj3US{BTMQ>?				Mmr2dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy\|	MoPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	Ml3WUmIyPjR\|				MnOydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?=	NV3HUIQyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	M{n4fG9JWy13MB?=				NU\yRmlYeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=>	M{D3VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	NGfVR5NNSU5vNR?=				MV\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDMRW4uPSClZXzsdy=>	NFXyN2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	Mn;NUmIuTUKlMR?=				MoG0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIuTUKlMTDj[Yxtew>?	Mk\MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	MlXuV2suVi2VSB?=				MVLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNVOKIHPlcIx{	MkTlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	M{ixWHJpPDF?				NFzQdXFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?=	NY[3OoF2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	MWHBOlc{				NEPQT29yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBCPjd\|IHPlcIx{MQ>?	NVfIZllzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	MVjSbFMx				NEjp[pVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnizNEBk\Wyucx?=	NXTtXmJnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	Mlm5RnQuOzd?				MoPxdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRnQuOzdiY3XscJM>	M3\0bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	NEPIeGlOTyB4MzCoOk1VTyCUKR?=				MoHSdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUWchPjNiKE[tWGchWiliY3XscJM>	M1vkdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	MUTSbFMx				NHHVSFJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDNyIHPlcIx{	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	Mly5U2hUNTVy				NV[0T5I1eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy\|	MkTpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	MYjTTk1ISk1{				MVHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	MkfaV2suVi2PQx?=				M3vmbJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	M{X4TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	NYHCOmI6VkJvRVLjNS=>				NW\DfIVieUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM>	NFv3W4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	NFi4[ZRNSU5vNR?=				M3u3OpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?=	NHy3WFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	NFHD[ZhTcDF6				NYrGdnVXeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO=	NX\Vd5cyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	MYfORlE3PDN?				NXfWUGQ2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy\|	NYPRTZlzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	NIfOVZRUUy2QLV3D				NU\tNFF[eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	NX7HXI5HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	NYXyW4d5XEN\|Mh?=				MkXudWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWGM{OiClZXzsdy=>	NUG5c\|lJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	MYTSbFE5				M4D1SpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOThiY3XscJM>	NEe4bXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	MoHjV4Fwey1{				M1TocJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNid3NvMjDj[Yxtew>?	MmHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Antiproliferative assay	M2DtSWVDSzF?		MWq3NkBpenN?		MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEWEQ{GgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHygWIl1\XJvR3zvJIF{e2G7LDDJR\|UxKD1iMD6wN\|kh\|ryPLh?=	MmD5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4MEKwN\|YoRjJ7NkCyNFM3RC:jPh?=
Function assay	M37BN2h{PTd6VB?=	MUKxNFAhdk1?	MVezNEBucW6\|		NEXhZXdKdmirYnn0bY9vKG:oIHjldJNqdi2vZXTpZZRm\CClb372[ZJ{cW:wIH;mJHBzdy2KR1[gbY51dyCjY4TpeoUh\m:{bTDpckBpfW2jbjDId\|U4QFRiY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gUWVVKHCqb4PwbI9zgWyjdHnvckBifCBzMECgcm0heHKnaX7jeYJifGWmIH\vdkA{OCCvaX7zJIZwdGyxd3XkJIJ6KHKnY3;tZolv[W62IHj1cYFvKHC{bz3IS2Yh[WSmaYTpc44hdWWjc4Xy[YQh[W[2ZYKgN\|AhdWmwczDifUBqdW23bn;icI91KG1?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTdyMUm2Nkc,Ojl5MEG5OlI9N2F-
Function assay	MUTIR2MyQTN5	NXn0bmc4OTByIH7N	MmD2N\|AhdWmwcx?=		M{jaPWlvcGmkaYTpc44hd2ZiaHXwd4lvNW2nZHnheIVlKGOxbo\ldpNqd25ib3[gVJJwNUiJRjDpcpRwKGGldHn2[UBnd3KvIHnuJIh2dWGwIFjDR\|E6OzdiY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gUWVVKHCqb4PwbI9zgWyjdHnvckBifCBzMECgcm0heHKnaX7jeYJifGWmIH\vdkA{OCCvaX7zJIZwdGyxd3XkJIJ6KHKnY3;tZolv[W62IHj1cYFvKHC{bz3IS2Yh[WSmaYTpc44hdWWjc4Xy[YQh[W[2ZYKgN\|AhdWmwczDifUBqdW23bn;icI91	NH3USZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUewNVk3Oid-Mkm3NFE6PjJ:L3G+
Antiproliferative assay	NY\oOodxVkOLLViyNlI5		MYG3NkBpenN?		M1PabmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWgzOjJ6IHPlcIx{KGijcnLvdolv\yCHTVy0MWFNUyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5yOEeg{txONg>?	MnKxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{MkOxNlAoRjNyMkKzNVIxRC:jPh?=
Antiproliferative assay	NH6xXWFJS0N5OB?=		NVvTU3pQPzJiaILz		NHHpd2hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDR\|c5KGOnbHzzJIhiemKxcnnu[{BUVEN\|NFGyMXJQWzFiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMUeg{txONg>?	NHP6d3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEKyN\|EzOCd-M{CyNlMyOjB:L3G+
Antiproliferative assay	NEn3eJBMSVKSQWOyPVk>		MWq3NkBpenN?		M4r1[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1HSVGFUOjl7IHPlcIx{KGijcnLvdolv\yCQUF2tRWxMKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjJ2IN88UU4>	M4PkOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkKzNVIxLz5\|MEKyN\|EzODxxYU6=
NB1	M3m1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTlzLkm4JI5O	NIDp[os9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
NCI-SNU-5	M3PLSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTITWM2OD1zMEWuO\|Uhdk1?	MkHZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
SR	M1H0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHP4UGtKSzVyPUGyOk4{OSCwTR?=	NVnmWmo{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
SF539	MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUi2c4N6UUN3ME2yNFQvOjRibl2=	MlPhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
SU-DHL-1	NX\3bFlFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnW0TWM2OD1\|M{[uPFIhdk1?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
SCC-3	Mo\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3TWIZKSzVyPUO1Ok44PiCwTR?=	M4roOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
DEL	M1q2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;JeWlEPTB;M{[5Mlkhdk1?	Mn7wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
CTV-1	NGH5e4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPkV2FsUUN3ME21PVYvPDhibl2=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
EM-2	NUTybVRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TtZmlEPTB;NkCxMlM1KG6P	MkfvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
MHH-CALL-2	NX3ub3BmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXnb5BKSzVyPU[4Nk42PyCwTR?=	M1HVWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
KM12	M4\RTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW[xT4FiUUN3ME23NFYvQSCwTR?=	M3nm[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
KINGS-1	NEHtNXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7yTWM2OD15NEmuO\|Uhdk1?	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
MEG-01	NWn2UVM3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPCT25KSzVyPUi1O{43PiCwTR?=	NHv4V2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
BV-173	NE\UOXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIK4TVhKSzVyPUGuNFU6QTdizszN	NEHRPWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
LAMA-84	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTFwM{iyPFIh\|ryP	NWCwT2hQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
KARPAS-299	Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTFwNEC4OlEh\|ryP	M3PxW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
K-562	NWHidG06T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfGRYJZUUN3ME2xMlczOjZ7IN88US=>	NUe3[FFsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
SK-LMS-1	NV2yWmx4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDlbZNKSzVyPUGuO\|Y5PjdizszN	M3S5e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
MOLT-16	NXPl[HJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXTTWM2OD1zLkm1OVc2KM7:TR?=	NGDsbZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
CMK	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoK1TWM2OD1zLkm2NVU6KM7:TR?=	MnX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
ST486	MoPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13IWGlEPTB;Mj60N\|A4OyEQvF2=	NHu5UoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
CI-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTJwNEm2OVkh\|ryP	M{DFflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
KP-N-RT-BM-1	M3X5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1ruc2lEPTB;Mj63NFEzOiEQvF2=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
ALL-PO	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkDmTWM2OD1\|LkG4NlA4KM7:TR?=	MmPOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
KS-1	Ml;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;Ge2hKSzVyPUOuNlEzOjVizszN	NWTWcodnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
Becker	NIK0XG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrLNFhxUUN3ME20MlI{QTNizszN	M3vWdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
GDM-1	M1vKbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXUPY5VUUN3ME20MlI1PjF5IN88US=>	NUTCN3lURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
BC-1	MnPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHOxUFFKSzVyPUSuOFkzPzdizszN	M2rVblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
NB14	NGPqV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTRwOEO1NlQh\|ryP	NXK4[HZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
NOS-1	NYH4XHZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPpOIxKSzVyPUWuN\|M5PzRizszN	Mn\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
MZ1-PC	NWHYO5NET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{nPemlEPTB;NT64NlE2OSEQvF2=	NXGyNG9ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
A498	NFzXc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fIfGlEPTB;Nj6wPFQ4OyEQvF2=	NUfrdm42RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
EW-16	NIHiNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEXRT2tKSzVyPU[uN\|c4PzNizszN	NWDXN4ppRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
NALM-6	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFflfINKSzVyPU[uOlg{QDdizszN	NY[1RWp2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
EB-3	NVPOXXZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTqTWM2OD15LkC3NlM{KM7:TR?=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
697	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NInubWZKSzVyPUmuNlQ{OjlizszN	NIj6NXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
Ramos-2G6-4C10	NYK1O41sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXu2[mlsUUN3ME25MlU6QDR{IN88US=>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
KNS-81-FD	NVjj[WZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTlwNkm2OVMh\|ryP	NVrHZnh4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
HUTU-80	M1z4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jyTGlEPTB;OT63OFY1OiEQvF2=	M1nNRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
LS-411N	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzCbJhOUUN3ME2xNE4xPTZ5IN88US=>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
RPMI-8402	NHrrNmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDwUXVKSzVyPUGwMlEyPiEQvF2=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
KU812	NF60NY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLPOZVkUUN3ME2xNE4zQTlzIN88US=>	NGCwfmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
EW-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M13McmlEPTB;MUCuOFQzPSEQvF2=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
HC-1	NYDoV4JXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HSOWlEPTB;MUCuOFg1PCEQvF2=	NIq4dYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
NB69	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4D3eGlEPTB;MUCuOVA1OyEQvF2=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
MFH-ino	M{j6TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmfxTWM2OD1zMD64N\|A{KM7:TR?=	NEK2d5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
CCRF-CEM	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXHvTWtZUUN3ME2xNU42QTdizszN	NInPb2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
SK-N-DZ	MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;HdWlEPTB;MUKuNFQ{PiEQvF2=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
NCI-H720	MkPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljNTWM2OD1zMj6xO\|A2KM7:TR?=	NWOyZ2xjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
HCC1187	NEDieIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1:2V2lEPTB;MUKuNlA1OSEQvF2=	NHzYW5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
IST-SL2	NH7DcItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;PTWM2OD1zMj60PFczKM7:TR?=	Ml3BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
KE-37	NFTLfnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDuTWM2OD1zMj63PVY3KM7:TR?=	Mn:wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
HCC1599	MnuwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLYTWM2OD1zMj65NFY6KM7:TR?=	NWX2bFlzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
A4-Fuk	MkDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3znemlEPTB;MUKuPVU5PiEQvF2=	NE\TZZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
NKM-1	MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUm5eo0{UUN3ME2xN{4zQTJ3IN88US=>	MlLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
BE-13	NIXTcppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnETWM2OD1zMz63PVg6KM7:TR?=	NG\CfGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
MV-4-11	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPvTWM2OD1zND6wN\|I1KM7:TR?=	Moj5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
OPM-2	MmK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWC2NJoxUUN3ME2xOE41ODh3IN88US=>	NH7Dem09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
KARPAS-422	NYXMe2kyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUny[FVrUUN3ME2xOE42OTJ4IN88US=>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
RPMI-8226	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3frO2lEPTB;MUSuPFkyPSEQvF2=	M1OwZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
KARPAS-45	NFnpeGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWC1Zml{UUN3ME2xOU44PzF4IN88US=>	NV7GZZBJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
SK-PN-DW	M3KzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjmUFZrUUN3ME2xOU45PjNzIN88US=>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
LC-2	M{jpWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTF4LkG1NFYh\|ryP	NEjB[4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
NCI-H1648	M3rJN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LKO2lEPTB;MU[uNlU1KM7:TR?=	MnrCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
RL95-2	M1HpTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIryb2VKSzVyPUG2MlM6PzhizszN	NFHzN4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
KNS-42	MoHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7x[ngyUUN3ME2xOk44Ojd2IN88US=>	NHrMfZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
RPMI-6666	NYH4SmJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\qOW91UUN3ME2xOk46OjFzIN88US=>	M2H2VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
SIG-M5	MmrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPSTWM2OD1zNz6xPVA{KM7:TR?=	NHH5fHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
VA-ES-BJ	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFH4dlJKSzVyPUG3Mlc1PTFizszN	M{HIWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
MONO-MAC-6	M{XzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV6xdnIxUUN3ME2xO{46OzF{IN88US=>	NEjnTng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
LAN-6	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzCPY1KSzVyPUG4Mlc2PTdizszN	MoLZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
A388	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULlUHY5UUN3ME2xPU4{ODV7IN88US=>	MkK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
SK-NEP-1	NWToWY1bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXn1ZWpWUUN3ME2yNE4zOTN{IN88US=>	NXX6XmNCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
TE-10	NIixXFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTBNFNiUUN3ME2yNE42OjJzIN88US=>	MoTOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
HL-60	M{jLSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEjIWopKSzVyPUKwMlkxQTlizszN	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
MC116	NH7hT5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTJzLkeyNlEh\|ryP	M1nnSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
SW962	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYfaN3REUUN3ME2yNU44QTF3IN88US=>	M2PCclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
NOMO-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmP3TWM2OD1{Mj62OVY1KM7:TR?=	NVXUdVZGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
CTB-1	NXHVcHQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7z[FhKSzVyPUKyMlg3PzFizszN	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
MRK-nu-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTJ{LkmwO\|Qh\|ryP	NYLEcmFYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
GR-ST	NXHNSoVQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTJ\|Lke2JO69VQ>?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
HH	NY[zRnZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHL1bohKSzVyPUK0MlAxOyEQvF2=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
NCI-H1963	MnO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4r5N2lEPTB;MkSuNFc5OiEQvF2=	Mkj1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
QIMR-WIL	MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTJ2Lki3O\|Ih\|ryP	Mo[1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
CGTH-W-1	M4OzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHOT2RuUUN3ME2yOU4xPzJ\|IN88US=>	M17zblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
LP-1	MnHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;4TWM2OD1{NT62OVUyKM7:TR?=	NGrlR5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
NCI-H748	NFj6fWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vOUWlEPTB;Mk[uOVE{PyEQvF2=	NFS4N3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
PF-382	NGnSU3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTJ5LkKyNlMh\|ryP	MmjrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
ATN-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXib25XUUN3ME2yO{4{PzN{IN88US=>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
L-540	NGj5OXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTJ5Lk[0OVkh\|ryP	NVTxR4xxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
LXF-289	M3PvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTJ5Lke1NVkh\|ryP	Mn65QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
LS-513	NH;xd2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTJ6LkG4NFch\|ryP	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
NCI-H1581	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmW2TWM2OD1\|MD6zPVc3KM7:TR?=	NVnrPGRNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
ES6	NFLVUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHWTWM2OD1\|MD62PFk6KM7:TR?=	NYDCeHZERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
SW982	MmPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrwflVUUUN3ME2zNE45PTZ4IN88US=>	NXTlUXBjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
DOHH-2	MnvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7Y[IdVUUN3ME2zNU42QDl\|IN88US=>	M2O1OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
DB	NWLZeVI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEGwdHJKSzVyPUOzMlk1OzFizszN	M1XnXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
MPP-89	NX;XZnlNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjndnJOUUN3ME2zOE4yPzV4IN88US=>	NYXV[4tMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
LB831-BLC	NXTUOXI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;SZZpMUUN3ME2zOE42OTh2IN88US=>	MknUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
NB5	M16xWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M364O2lEPTB;M{SuPFU{PSEQvF2=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
GB-1	MlPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTN3LkC0Olkh\|ryP	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
TE-15	NGOxXYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTN3LkKyN\|gh\|ryP	NGHRXos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
LC4-1	MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\ZXGRKSzVyPUO1MlM5PDdizszN	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
NCI-H747	M13t[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPLPVJCUUN3ME2zOk4yOzZ7IN88US=>	MnHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
NTERA-S-cl-D1	NHXtUIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIKwbVRKSzVyPUO4Mlc{PDdizszN	NG\YVYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
SK-MM-2	MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TVNWlEPTB;NECuNVE1PiEQvF2=	NWLPTYJ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
TGW	M1zrcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTRzLkC1OlMh\|ryP	M1XR[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
ONS-76	NUDkZ4VOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjKN4tvUUN3ME20Nk41QDh\|IN88US=>	NEj4Z4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
CPC-N	NUPCemdsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTR{Lkm5O\|Eh\|ryP	NHPjdYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
ES4	M{\n[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnmNYdtUUN3ME20OE41OTV\|IN88US=>	NW\oZmtYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
Daudi	NUfBV3V6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPR[WlMUUN3ME20OU4xQDJ5IN88US=>	NH3ZU4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
MOLT-4	NGDCOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7PbndIUUN3ME20OU4xQDV\|IN88US=>	NWTrSYVNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
HT-144	M{C3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEjaTGZKSzVyPUS2MlczPiEQvF2=	M2m5[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
SW872	M3zEPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TKTGlEPTB;NEiuNVk{OyEQvF2=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
D-283MED	M3vXcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XJWWlEPTB;NEiuN\|U1OiEQvF2=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
NCI-H2126	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTR6Lki0O\|Yh\|ryP	MmfoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
NCI-SNU-16	MmjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTR7LkKxOFMh\|ryP	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
CESS	MmPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTR7LkWwPFgh\|ryP	NUDacXhSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
A101D	M3vtWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\wN5VKSzVyPUS5Mlk4OzZizszN	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pALK / pAKT / pERK / pS6; PubMed: 24675041 Cancer Discov H3122 cells were treated with the indicated concentrations of crizotinib or ceritinib for 6 hours. Lysates were probed with antibodies directed against the specified proteins. pROS1 / ROS1; PubMed: 25351743 Clin Cancer Res Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins. pSTAT3 / STAT3; PubMed: 25351743 Clin Cancer Res Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins. PARP / cleaved caspase-3 / Bax / Bcl-2; PubMed: 25193856 Oncotarget The expression of PARP, cleaved caspase-3, Bax, and Bcl-2 were measured by western blotting after PANC-1 cells were treated with various concentrations of Crizotinib (0-10 μM) for 72 hr. p-c-Met / c-Met; PubMed: 25193856 Oncotarget Cancer cells with c-MET alterations were exposed to Crizotinib (10 μM) in the indicated times (SNU-5, MKN-45, and SNU-638: gastric cancer cells of c-MET amplification). p-mTOR; PubMed: 26384345 Oncotarget Immunoblotting for phospho- or total MET, STAT3, AKT, MTOR and ERK in SPC-A1 cells treated with crizotinib for 48 h.	24675041 25351743 25193856 26384345
Immunofluorescence	LC3 / lysosome; PubMed: 26384345 Oncotarget Cells were treated with DMSO or 4 μM crizotinib for 72 h before they were labeled with a fluorescent marker and imaged by fluorescence microscopy. Green: FITC-labeled LC3; Red: lyso-tracker-labeled lysosome; Blue: DAPI-labeled nucleus. SRC / Met; PubMed: 26517812 Oncotarget Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in (A) LN-18 and (B) U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively. α-tubulin; PubMed: 26517812 Oncotarget LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm. cytochrome c; PubMed: 25193856 Oncotarget PANC-1 pancreatic cancer cells were treated with Crizotinib (1 and 10 μM) for 6 hr and stained with anti-cytochrome c antibody, Mitotracker and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification. Cytochrome c (green), mitotracker: red p-ALK; PubMed: 25193856 Oncotarget PANC-1 cells were also treated with various concentrations (0-10 μM) of Crizotinib and stained with p-ALK antibody and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification.	26384345 26517812 25193856

In vivo

In the GTL-16 model, PF-2341066 reveals the ability to cause marked regression of large established tumors (>600 mm³) in both the 50 mg/kg/day and 75 mg/kg/day treatment cohorts, with a 60% decrease in mean tumor volume over the 43-day administration schedule. In an another study, PF-2341066 displays the ability to completely inhibits GTL-16 tumor growth for >3 months, with only 1 of 12 mice exhibiting a significant increase in tumor growth over the 3-month treatment schedule at 50 mg/kg/day. In the NCI-H441 NSCLC model, a 43% decrease in mean tumor volume is observed at 50 mg/kg/day during the 38-day PF-2341066 administration cycle. In the Caki-1 RCC model, a 53% decrease in mean tumor volume is observed to be associated with decreased volume of each tumor by at least 30% at 50 mg/kg/day during the 33-day PF-2341066 administration cycle. PF-2341066 also reveals near-complete prevention of the growth of established tumors at 50 mg/kg/day in the U87MG glioblastoma or PC-3 prostate carcinoma xenograft models, with 97% or 84% inhibition on the final study day, respectively. In contrast, PF-2341066 p.o. given at 50 mg/kg/day does not significantly inhibit tumor growth in the MDA-MB-231 breast carcinoma model, or the DLD-1 colon carcinoma model. A significant dose-dependent reduction of CD31–positive endothelial cells is observed at 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day in GTL-16 tumors, indicating that inhibition of MVD shows a dose-dependent correlation to antitumor efficacy. PF-2341066 displays a significant dose-dependent reduction of human VEGFA and IL-8 plasma levels in both the GTL-16 and U87MG models. Marked inhibition of phosphorylated c-Met, Akt, Erk, PLCλ1, and STAT5 levels is observed in GTL-16 tumors following p.o. administration of PF-2341066.^[1] P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts leads to dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compound administration. In addition, inhibition of key NPM-ALK signaling mediators, including phospholipase C-gamma, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 are observed at concentrations or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.^[2] PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (eg, proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). In nude mice treated with PF-2341066 via oral gavage, the growth and associated osteolysis and extracortical bone matrix formation of osteosarcoma xenografts are prevented by PF-2341066.^[3] Treatment of c-MET-amplified GTL-16 xenografts with 50 mg/kg PF-2341066 elicits tumor regression that is associated with a slow reduction in ¹⁸F-FDG uptake and decreases expression of the glucose transporter 1, GLUT-1.^[4]

Protocol

Kinase Assay: ^[1]	- Collapse Cellular kinase phosphorylation ELISA assays: Cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 min. After incubation of cells with PF-2341066 for 1 h and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na₃VO₄, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4°C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3′,5,5′-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H₂SO₄; and (f) measured for absorbance in 450 nm using a spectrophotometer.
Cell Research: ^[1]	- Collapse Cell lines: GTL-16 gastric carcinoma cells and T47D breast carcinoma cells Concentrations: 0-256 nM Incubation Time: 1 hour Method: Cells including GTL-16 gastric carcinoma cells and T47D breast carcinoma cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 hours. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 minutes. After incubation of cells with PF-2341066 for 1 hour and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na₃VO₄, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4 °C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3^′,5,5^′-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H₂SO₄; and (f) measured for absorbance in 450 nm using a spectrophotometer. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Female or male nu/nu mice bearing NCI-H441,or DLD-1, or MDA-MB-231 Dosages: 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day Administration: Administered via p.o. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	9 mg/mL (19.98 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+dd H2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Crizotinib (PF-02341066) SDF

Molecular Weight	450.34
Formula	C₂₁H₂₂Cl₂FN₅O
CAS No.	877399-52-5
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04148066	Recruiting	Diagnostic Test: ctDNA blood sample	Carcinoma Non-Small-Cell Lung	The Netherlands Cancer Institute\|Roche Pharma AG	July 17 2019	Phase 2
NCT03439215	Recruiting	Drug: Lorlatinib	Carcinoma Non-Small-Cell Lung	Fondazione Ricerca Traslazionale\|Clinical Research Technology S.r.l.	June 13 2017	Phase 2
NCT02946216	Unknown status	Genetic: ctDNA analysis	Non-small Cell Lung Cancer Stage III\|Non-Small-Cell Lung Cancer Metastatic\|Adenocarcinoma of Lung\|EGFR Wildtype	First People''s Hospital of Hangzhou	November 2016	--
NCT02511184	Terminated	Drug: Crizotinib\|Drug: Pembrolizumab	ALK-positive Advanced NSCLC	Pfizer\|Merck Sharp & Dohme Corp.	October 2015	Phase 1
NCT02419287	Active not recruiting	Drug: crizotinib	Anaplastic Large Cell Lymphoma ALK-Positive	University of Milano Bicocca	April 2015	Phase 2
NCT02499614	Unknown status	Drug: Crizotinib	Carcinoma Non-Small-Cell Lung	Fondazione Ricerca Traslazionale	December 2014	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?
Answer:
Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

Selective c-Met Inhibitor

PF-04217903 : C-Met-selective, IC50=4.8 nM.
Most Potent c-Met Inhibitor

INCB28060 : C-Met, IC50=0.13 nM.
c-Met Inhibitor in Clinical Trial

Tivantinib (ARQ 197) : Phase III for Hepatocellular Carcinoma.
Newest c-Met Inhibitor

EMD 1214063 ^New : Potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer.

Related c-Met Products

NPS-1034 ^New

NPS-1034 is a dual Met (c-Met)/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.
Erlotinib ^New

Erlotinib (CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Bemcentinib (R428) ^New

Bemcentinib (R428, BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
Foretinib (GSK1363089)

Foretinib (GSK1363089, EXEL-2880, XL-880) is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met (c-Met) and KDR with IC50 of 0.4 nM and 0.9 nM in cell-free assays. Less potent against Ron, Flt-1/3/4, Kit (c-Kit), PDGFRα/β and Tie-2, and little activity to FGFR1 and EGFR. Phase 2.
Capmatinib (INCB28060)

Capmatinib (INCB28060, INC280, NVP-INC280) is a novel, ATP-competitive inhibitor of c-MET with IC50 of 0.13 nM in a cell-free assay, inactive against RONβ, as well as EGFR and HER-3. Capmatinib (INCB28060) inhibits Wnt/β-catenin and EMT signaling pathways and induces apoptosis in diffuse gastric cancer positive for c-MET amplification. Phase 1.

Features:Inactive against RONβ, another member of the c-MET RTK family, as well as EGFR and HER-3 (members of the EGFR RTK family).
Tivantinib (ARQ 197)

Tivantinib (ARQ 197) is the first non-ATP-competitive c-Met inhibitor with K_i of 0.355 μM in a cell-free assay, little activity to Ron, and no inhibition to EGFR, InsR, PDGFRα or FGFR1/4. Tivantinib (ARQ 197) induces a G2/M arrest and apoptosis. Phase 3.

Features:The first selective c-Met inhibitor to be advanced into human clinical trials.
PHA-665752

PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM in cell-free assays, >50-fold selectivity for c-Met than RTKs or STKs.
BMS-777607

BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM in cell-free assays, 40-fold more selective for Met-related targets versus Lck, VEGFR-2, and TrkA/B, and more than 500-fold greater selectivity versus all other receptor and non receptor kinases. Phase 1/2.

Features:A potent inhibitor of the Met family, and >40-fold selectivity vs. Lck, VEGFR2, and TrkA/B and >500-fold selective vs. other receptor and non-receptor kinases.
PF-04217903

PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM in A549 cell line, susceptible to oncogenic mutations (no activity to Y1230C mutant). Phase 1.
SU11274

SU11274 (PKI-SU11274) is a selective Met (c-Met) inhibitor with IC50 of 10 nM in cell-free assays, no effects on PGDFRβ, EGFR or Tie2. SU11274 induces autophagy, apoptosis and cell cycle arrest.

Choose Your Country or Region

By Signaling Pathways

By product type

Crizotinib (PF-02341066)